

1 **Contents**

2	Contents.....	1
3	Section 1. Supplementary Methods	2
4	Section 1.1. Meta-analysis of smoking and physical activity for PD	2
5	Section 1.2. Estimation of PD prevalence in GBD 2021	4
6	Section 1.3. Model ensemble	4
7	Section 1.4. Measuring the performance of Bayesian model average projections	6
8	Section 1.5. Temporal trend of PD prevalence.....	6
9	Section 1.6. Decomposition analysis	7
10	Section 1.7. PAFs estimation.....	7
11	Section 1.8. PIFs estimation.....	8
12	Section 1.9. Plain English Summary	8
13	Section 1.10. Spatial weight matrix and spatial autocorrelation	9
14	Section 2. Supplementary Figures.	10
15	Figure S1.....	10
16	Figure S2.....	11
17	Figure S3.....	12
18	Figure S4.....	13
19	Figure S5.....	14
20	Figure S6.....	15
21	Figure S7.....	16
22	Figure S8.....	17
23	Figure S9.....	18
24	Figure S10.....	19
25	Figure S11.....	20
26	Section 3. Supplementary Tables.....	21
27	Table S1.	21
28	Table S2.	23
29	Table S3	24
30	Table S4..	26
31	Table S5	42
32	References	58

33
34

Section 1. Supplementary Methods

Section 1.1. Meta-analysis of smoking and physical activity for PD

Based on 7 eligible studies included in the meta-analysis published in 2024, we recalculated the PR of PD associated with physical activity.¹ Our results indicated that physical activity was associated with a decreased risk of PD (PR = 0.83, 95% CI 0.78 to 0.88, $I^2 = 88\%$) (Figure 1).




Figure 1. Forest plot of the PR with 95% CIs of PD associated with physical activity. The size of the gray box is positively proportional to the weight assigned to each study, and the horizontal lines represent the 95% CIs.

Based on the published meta-analysis published in 2012,² we performed an updated meta-analysis to estimate the PR of PD for smoking. PubMed, Web of Science, and Embase were systematically searched from January 1, 2012 to August 23, 2024, using the following keywords for the literature search: (“smoking” OR “smoking behaviors” OR “smoking habit”) AND (“Parkinson disease” OR “Parkinson’ s disease” OR “Parkinsons disease”). Studies were considered eligible if they met the following criteria: (a) the exposure of interest was smoking; (b) the outcome of interest was PD; (c) studies that provided sufficient information regarding PR and 95% confidence intervals (CI); (d) analytical studies (cohort studies and case-control studies); and (e) smoking was defined as current smoking of any tobacco product. Studies were excluded if they were review articles, case reports, protocols, meeting abstracts, letters, comments, short communications, posters, or reports.

The search strategy identified 156 articles from PubMed, 99 articles from Web of Science, and 1,155 articles from Embase, along with 71 articles identified through the bibliographies of the previous meta-analysis published in 2012. After duplicates were removed, an additional 1,211 articles were excluded during the screening of titles and/or abstracts. Finally, 21 studies were included in this meta-analysis (Figure 2).




Figure 2. Flowchart of studies selection.

The meta-analysis indicated that smoking was associated with a decreased risk of PD (PR = 0.57, 95% CI 0.53 to 0.61, $I^2 = 84\%$) (Figure 3).




Figure 3. Forest plot of the PR with 95% CIs of PD associated with smoking. The size of the gray box is positively proportional to the weight assigned to each study, and the horizontal lines represent the 95% CIs.

1 **Section 1.2. Estimation of PD prevalence in GBD 2021**

2 For PD, large inconsistencies existed between the cause of death data and the prevalence data, likely due to
3 inconsistencies in coding practices for certifying deaths from PD. To address this issue, the GBD project modelled PD
4 mortality and prevalence estimates jointly. Prevalence data were obtained from systematic review of the published
5 literature, survey data, cohort studies, and claims sources, while mortality data came from vital registration and
6 surveillance systems. The GBD project used the CODEm model to estimate age-, sex-, location-, and year-specific
7 mortality rates for PD in 2021, and Bayesian meta-regression model (DisMod MR-2.1) to generate prevalence estimates
8 for PD by age, sex, location, and year. In DisMod MR-2.1 model, medical claims data was adjusted to correct for any
9 systematic under-reporting and datapoints with case definitions that differed from the reference. Country-level covariates
10 of smoking prevalence and social development index (SDI) were also included. The initial DisMod MR-2.1 model results
11 identified countries with the highest ratios of cause-specific mortality to prevalence. Using these ratios as input data for a
12 second DisMod MR-2.1 model, which was identical to the first model, age- and sex-specific ratios for the full 1990-2021
13 estimation period were retained. The cause-specific prevalence results from this second model were used as final outputs,
14 ensuring consistency between non-fatal input data and the excess mortality rate in 2021 from countries most likely to code
15 PD as a cause of death. The general Global Burden of Disease Study Methods is reported elsewhere.³

16 **Section 1.3. Model ensemble**

17 **Section 1.3.1. Model 1**

18 The projected prevalence of PD from 2022 to 2050 was estimated with country-, age- and sex-stratified Poisson regression
19 using the following regression model:

$$E[\log(Y_{l,a,s,y})] = \beta_l SDI_{l,y} + \alpha_{l,a,s}$$

20 For each location (l), age group (a), sex (s), and year (y), we log-transformed the PD prevalence estimates $\log(Y_{l,a,s,y})$. On
21 the right side of the equation, β_l was the fixed coefficient on forecasted location-year-specific $SDI_{l,y}$, $\alpha_{l,a,s}$ was the
22 location-age-sex-specific random intercept.

23 **Section 1.3.2. Model 2**

24 The projected prevalence of PD from 2022 to 2050 was estimated with country-, age- and sex-stratified Poisson
25 regression using the following regression model:

$$E[\log(Y_{l,a,s,y})] = \beta_l SDI_y + \sum_{a=1}^{16} \beta_a \times Age\ group_a + \alpha_{l,a,s}$$

For each location (l), age group (a), sex (s), and year (y), we log-transformed the PD prevalence estimates $\log(Y_{l,a,s,y})$. On the right side of the equation, β_l was the fixed coefficient on forecasted SDI, $\alpha_{l,a,s}$ was the location-age-sex-specific random intercept.

Section 1.3.3. Model 3

The projected prevalence of PD from 2022 to 2050 was estimated with country-, age- and sex-stratified Poisson regression using the following regression model:

$$E[\log(Y_{l,a,s,y})] = \beta_l SDI_{l,y} + \sum_{a=1}^{16} \beta_a \times Age\ group_a + \alpha_{l,a,s}$$

For each location (l), age group (a), sex (s), and year (y), we log-transformed the PD prevalence estimates $\log(Y_{l,a,s,y})$. On the right side of the equation, β_l was the fixed coefficient on forecasted location-year-specific $SDI_{l,y}$, $\alpha_{l,a,s}$ was the location-age-sex-specific random intercept.

Section 1.3.4. Model 4

The projected prevalence of PD from 2022 to 2050 was estimated with country-, age- and sex-stratified Poisson regression⁴ using the following regression model⁴⁻⁶:

$$E[\log(Y_{l,a,s,y})] = \beta_l SDI_{l,y} + \alpha_{l,a,s}$$

For each location (l), age group (a), sex (s), and year (y), we log-transformed the PD prevalence estimates $\log(Y_{l,a,s,y})$. On the right side of the equation, β_l was the fixed coefficient on forecasted location-year-specific $SDI_{l,y}$, $\alpha_{l,a,s}$ was the location-age-sex-specific random intercept. Ultimately, to address trends not elucidated by our covariates, we applied a random walk model (autoregressive integrated moving average [ARIMA (0,1,0)]) to the residuals of our regression models and incorporated forecasts of these residuals into our estimated predictions.

Section 1.3.5. Model 5

The projected prevalence of PD from 2022 to 2050 was estimated with country-, age- and sex-stratified Poisson regression using the following regression model:

$$E[\log(Y_{l,a,s,y})] = \beta_l SDI_y + \sum_{a=1}^{16} \beta_a \times Age\ group_a + \alpha_{l,a,s}$$

For each location (l), age group (a), sex (s), and year (y), we log-transformed the PD prevalence estimates $\log(Y_{l,a,s,y})$. On the right side of the equation, β_l was the fixed coefficient on forecasted SDI, $\alpha_{l,a,s}$ was the location-age-sex-specific random

intercept. Ultimately, to address trends not elucidated by our covariates, we applied a random walk model (autoregressive integrated moving average [ARIMA (0,1,0)]) to the residuals of our regression models and incorporated forecasts of these residuals into our estimated predictions.

Section 1.3.6. Model 6

The projected prevalence of PD from 2022 to 2050 was estimated with country-, age- and sex-stratified Poisson regression using the following regression model:

$$E[\log(Y_{l,a,s,y})] = \beta_l SDI_{l,y} + \sum_{a=1}^{16} \beta_a \times Age\ group_a + \alpha_{l,a,s}$$

For each location (l), age group (a), sex (s), and year (y), we log-transformed the PD prevalence estimates $\log(Y_{l,a,s,y})$. On the right side of the equation, β_l was the fixed coefficient on forecasted location-year-specific $SDI_{l,y}$, $\alpha_{l,a,s}$ was the location-age-sex-specific random intercept. Ultimately, to address trends not elucidated by our covariates, we applied a random walk model (autoregressive integrated moving average [ARIMA (0,1,0)]) to the residuals of our regression models and incorporated forecasts of these residuals into our estimated predictions.

Section 1.4. Measuring the performance of Bayesian model average projections

To measure the performance of the BMA framework, we withheld 11 (2011-2021) recent years of data to validate our approach. The period of 11 years is supported by findings in other studies and allowed the sufficient remaining data to be used to generate the BMA projections. We used the remaining data to produce BMA projections for this withheld period, and examined how well the BMA projections reproduce the withheld data. To quantify the prediction performance, the projections were then compared with the withheld data by calculating the summary root mean squared error (RMSE) and bias. Bias was calculated as the median value of all predicted minus observed values by age, sex, year, and location. Besides, the projection bias of the model with the smallest projection bias over the same period (2011-2021) was calculated to see how the BMA projection performs relative to the best model for each country and sex. Furthermore, we examined whether both the BMA and the best model demonstrated significantly better or worse performance in shorter versus longer-term projections. To accomplish this, we replicated the aforementioned process, adjusting the duration of withheld data from 1 year (2011) to 11 years (2021), aligning with shorter and longer projection periods, respectively.

Section 1.5. Temporal trend of PD prevalence

Joinpoint regression analysis was used to examine the temporal trends in the prevalence of PD at the global, regional,

and national levels. This analysis facilitated the identification of significant turning points, known as joinpoints, that mark substantial changes in the trends. Based on these joinpoints, the overall trend was segmented into multiple subsegments, enabling an assessment of the epidemiological trend within each subsegment. The trends were expressed as annual percentage changes (APCs), and Z tests were utilized to determine whether the APCs deviated significantly from zero. Additionally, the average APC (AAPC) was calculated as a weighted average of APC, taking into account the duration of each segmented interval, providing a comprehensive summary of the trend during 2021-2050. This analysis was performed using Joinpoint software (version 5.0.1) developed by the Surveillance Research Program of the US National Cancer Institute (Bethesda, MD, USA).^{7 8}

Section 1.6. Decomposition analysis

A Das Gupta decomposition analysis was performed to determine the relative contributions to the change in number of cases between 2021 and 2050 of population growth, population aging, and changes in age-specific prevalence⁹. The method allowed for a meticulous examination of various components affecting prevalence rates, thereby substantiating the assertion that alterations in the age structure of the population substantially influence the projected increasing in PD prevalence.

Section 1.7. PAFs estimation

The modifiable factors of PD in this study were selected on the basis of the following criteria: evidence of causation with PD; sufficient data on population exposure and risk levels, or appropriate methods for extrapolation when necessary; and potentially modifiable. The World Cancer Research Fund evidence grading criteria was used to separately assess the strength of the epidemiologic evidence on the causal relationship between each exposure factor and the incidence of PD. Only factors with convincing or probable evidence on their relationship with PD were included. In this study, two modifiable factors for PD were eligible: smoking, and physical activity (supplementary table S2). Smoking was defined as current smoking of any tobacco product, and physical activity was defined as moderate to vigorous intensity activity. PAFs were employed to quantify the proportion of PD cases that would be reduced if exposure to a given factor was entirely eliminated. It was assumed that the association between modifiable factors and PD was constant worldwide.

PAFs are defined as the fraction of all cases of a particular disease or other adverse condition in a population that is attributable to a specific exposure.¹⁰⁻¹³ In this study, PAFs quantify the proportional reduction in PD cases that would occur if exposure to the given factor was completely eliminated. For polytomous exposure (e.g., smoking, physical activity), we use the categorical (Levin) epidemiological measurement to estimate PAFs with the following mathematical formula,^{14 15}

where p is the estimated population prevalence rate of a risk factor, and PR is the prevalence ratio of PD associated with exposure to this risk/protective factor. Specifically, for protective factors, p is the prevalence of individuals not in the low-risk group.

$$PAFs = \frac{p(PR - 1)}{1 + p(PR - 1)}$$

The association between a risk factor or protective factor and PD was assumed to be constant worldwide, and subsequently a single PR estimate was used in the calculation of each PAFs. The estimated total number of PD cases attributable to each risk/protective factor was estimated by multiplying the PAFs estimates by the current number of cases of PD in each country.

Section 1.8. PIFs estimation

The adjusted PAFs of each factor represent the maximum hypothetical proportion of PD cases that could potentially be prevented by solely eliminating the specific risk factor or advocate for protectable factor, without considering other factors. It is important to note the complete elimination of risk factors or advocacy of protective factor for PD may not be realistic. Therefore, we focused on more practical scenarios by considering the PIFs resulting from proportionally reducing (e.g., 20%) each risk factor or increasing each protective factor.¹⁶ This was modeled using Barendregt and Veerman's formula, where p' is the counterfactual prevalence rate of a risk/protective factor following a proportional reduction or increase (e.g., 20%).¹⁶

$$Potential\ impact\ fraction(PIFs) = \frac{(p - p')(PR - 1)}{p(PR - 1) + 1}$$

Section 1.9. Plain English Summary

Parkinson's disease (PD) is the neurological disease with the fastest-growing prevalence and disability. This study aimed to provide comprehensive projections of the global, regional, and national prevalence of PD and to analyze its drivers until 2050. The present projection was a study based on data from GBD 2021. By utilizing an ensemble of models, we incorporated six projection models, all of which employed the regression method.

In 2050, it was projected that 25.2 million individuals would be living with PD worldwide, representing a 112% increase since 2021. Population aging would be the main contributor to the increase in number of PD cases. The prevalence of PD was forecasted to be 267 per 100 000 population in 2050, indicating a significant increase of 76% from 2021.

1 The largest number of PD cases was projected to be in East Asia and South Asia in 2050. The largest increases in the
2 number of PD cases were estimated to occur in Western Sub-Saharan Africa and Eastern Sub-Saharan Africa during
3 2021-2050. Furthermore, the prevalence of PD was anticipated to be highest in East Asia in 2050. The regions with the
4 highest increase in prevalence were estimated to be North Africa and Middle East from 2021 to 2050. The increase in PD
5 prevalence between 2021 and 2050 was forecasted to be highest among countries with the middle Socio-demographic
6 index (SDI) and lowest among countries with the high SDI. In 2050, about two-thirds of cases would be found in ten
7 countries, with China, India, and the United States of America having the highest number of PD cases. The age group of
8 80 years and above was projected to have the highest prevalence in 2050 and the highest increase in the number of PD
9 cases from 2021 to 2050. The male-to-female ratios of age-standardized prevalence of PD were projected to increase from
10 1.46 in 2021 to 1.64 in 2050 globally. Physical activity is a protective factor for PD. Globally, if all individuals adhere to
11 regular physical activity, the projected number of PD would exhibit a reduction of 5% in 2050.


12 PD will become a greater public health challenge for patients, their families, caregivers, communities, and society by
13 2050. The substantial upward trend in the projected prevalence and number of PD cases necessitates targeted strategies
14 and measures. Our prediction could benefit people with PD (PwP) by promoting health research to prevent PD, improving
15 the quality of life of PwP, promoting drug and non-drug therapies, and focusing on the needs of countries with poorer
16 healthcare provision.

17 **Section 1.10. Spatial weight matrix and spatial autocorrelation**


18 To investigate the impact of spatial autocorrelation on our projection, we incorporated a spatial weight matrix into our
19 model. To establish adjacency of countries, we defined a simple spatial $n \times n$ matrix, W , using shape files that list country
20 boundaries as an ordered set of geocoded reference points. Country adjacency was defined by queen congruity (at least 1
21 shared boundary point), and the spatial weight matrix was row standardized, i.e., for each country i , the weight of link to
22 country j , w_{ij} , is the inverse of the number of neighbors of i , if j was adjacent to i , and 0 otherwise; $\sum_j w_{ij} = 1$. A country
23 was assumed to not be a neighbor of itself, i.e., $w_{ij} = 0$ when $i = j$. Then, utilizing prevalence data from 1990 to 2010, we
24 applied the revised model controlling for spatial autocorrelation to project the number of PD cases for the years 2011 to
25 2021. To quantify the projection bias, we compared these projections with data reported by GBD 2021 and calculated the
26 RMSE in 195 countries and territories by age and sex from 2011 to 2021. The RMSE for the revised model (RMSE:
27 201400) was higher than that of our original model (RMSE: 179100), indicating that incorporating spatial autocorrelation
28 did not improve the model's predictive accuracy. Thus, incorporating spatial autocorrelation into the present model may
29 not be suitable for predicting the prevalence of PD.

Section 2. Supplementary Figures.


Figure S1. Model weights of BMA framework for the 6 models for 21 GBD regions and the world. Detailed descriptions of 6 models have been described in Supplementary Section 1.3.




1 **Figure S2. Projected number of PD cases among different age groups by GBD regions in 2050.**




1 **Figure S3. Age-standardized prevalence rates (ASR) for PD per 100 000 population for 21 Global Burden of Disease**
 2 **regions by Socio-demographic index, 2021-2050.** The black line represents expected values based on
 3 Socio-demographic index and age-standardized rates in all locations. Sixty-one points are plotted for each Global Burden
 4 of Disease region and show observed age-standardized prevalence from 2021 to 2050.




1 **Figure S4. The projected number of PD cases in 2050 (A) and its AAPC (B) by country and territory for both sexes**
2 **combined during 2021-2050. Publisher’s note: Published maps are provided without any warranty of any kind,**
3 **either express or implied. BMJ remains neutral with regard to jurisdictional claims in published maps.**




1 **Figure S5. Projected global number of PD cases for females and males by age in 2030, 2040, and 2050**




1 **Figure S6. Projected prevalence of PD in 2050 (A) and its AAPC from 2021 to 2050 (B) by age group globally;**
2 **projected number of PD cases in 2050 (C) and its AAPC from 2021 to 2050 (D) by age group globally.**




1 **Figure S7. Projected number of PD cases in 2050 (A) and its AAPC from 2021 to 2050 (B) by age group in locations**
2 **grouped by socio-demographic index (SDI) quintiles; projected prevalence of PD in 2050 (C) and its AAPC from**
3 **2021 to 2050 (D) by age group in locations grouped by socio-demographic index quintiles.**




1 **Figure S8. Male-to-female ratio of age-standardized prevalence PD globally and in different SDI regions in 2021 and**
2 **2050.**




1 **Figure S9. Male-to-female ratio of age-standardized prevalence PD globally and in different SDI regions in 2021 and**
2 **2050.**



1 **Figure S10. Projection bias in prevalence of PD by length of validation period.** The average projection bias from the
2 model average is compared with that resulting from the best model for each sex and validation period. The data used in the
3 graph is the average projection bias for validation periods of 1-11 years.



1 **Figure S11. Prediction performance of our model globally during a test period (2011-2021).**



1 **Section 3. Supplementary Tables**

2 **Table S1. Checklist of information that should be included in new reports of global health estimates.**

Item #	Checklist item	Reported on section #
Objectives and funding		
1	Define the indicator(s), populations (including age, sex, and geographic entities), and time period(s) for which estimates were made.	Methods, Paragraph 2-3
2	List the funding sources for the work.	Founding statement
Data Inputs		
<i>For all data inputs from multiple sources that are synthesized as part of the study:</i>		
3	Describe how the data were identified and how the data were accessed.	Methods, Paragraph 2-3
4	Specify the inclusion and exclusion criteria. Identify all ad-hoc exclusions.	Methods, Paragraph 2-3
5	Provide information on all included data sources and their main characteristics. For each data source used, report reference information or contact name/institution, population represented, data collection method, year(s) of data collection, sex and age range, diagnostic criteria or measurement method, and sample size, as relevant.	Methods, Paragraph 2-3
6	Identify and describe any categories of input data that have potentially important biases (e.g., based on characteristics listed in item 5).	Methods, Paragraph 2-3
<i>For data inputs that contribute to the analysis but were not synthesized as part of the study:</i>		
7	Describe and give sources for any other data inputs.	Methods, Paragraph 2-3
<i>For all data inputs:</i>		
8	Provide all data inputs in a file format from which data can be efficiently extracted (e.g., a spreadsheet rather than a PDF), including all relevant meta-data listed in item 5. For any data inputs that cannot be shared because of ethical or legal reasons, such as third-party ownership, provide a contact name or the name of the institution that retains the right to the data.	Methods, Paragraph 2-3
Data analysis		
9	Provide a conceptual overview of the data analysis method. A diagram may be helpful.	Methods, Paragraph 3-8
10	Provide a detailed description of all steps of the analysis, including mathematical formulae. This description should cover, as relevant, data cleaning, data pre-processing, data adjustments and weighting of data sources, and mathematical or statistical model(s).	Methods, Paragraph 3-8
11	Describe how candidate models were evaluated and how the final model(s) were selected.	Methods, Paragraph 4-6
12	Provide the results of an evaluation of model performance, if done, as well as the results of any relevant sensitivity analysis.	Results, Paragraph 7
13	Describe methods for calculating uncertainty of the estimates. State which sources of uncertainty were, and were not, accounted for in the uncertainty analysis.	Methods, Paragraph 9

14	State how analytic or statistical source code used to generate estimates can be accessed.	Section of code availability
Results and Discussion		
15	Provide published estimates in a file format from which data can be efficiently extracted.	Results, Paragraph 1-6; Table1; Supplementary table S3, S4, S5.
16	Report a quantitative measure of the uncertainty of the estimates (e.g. uncertainty intervals).	Results, Paragraph 1-6
17	Interpret results in light of existing evidence. If updating a previous set of estimates, describe the reasons for changes in estimates.	Discussion, Paragraph 3-9
18	Discuss limitations of the estimates. Include a discussion of any modelling assumptions or data limitations that affect interpretation of the estimates.	Limitations of study

This checklist should be used in conjunction with the GATHER statement and Explanation and Elaboration document, found on gather-statement.org

Table S2. Epidemiological evidence supporting causality between risk factors and disease endpoints.

	Prospective	Prospective observational studies	Case-control studies assessing	Case-control studies that	Biological	WCRF grades
Modifiable factors	observational	with significant association in the	the risk-outcome pair	show significant association in	plausibility	
	studies (n)	opposite direction (%)	relationship (n)**	the opposite direction (%)		
Smoking	18 ¹⁷⁻³⁴	0	25 ³⁵⁻⁵⁹	0	Yes	Convincing
Physical activity	12 ^{30 33 60-69}	0	5 ⁷⁰⁻⁷⁴	0	Yes	Convincing

Table S3. Average annual percent changes (AAPC) in counts, all-age prevalence and age-standardized prevalence rates of PD from 1990 to 2021, as well as from 2021 to 2050 by SDI and GBD regions.

Location	AAPC (number of cases)		AAPC (all-age prevalence)		AAPC (age-standardized prevalence)	
	1990-2021	2021-2050	1990-2021	2021-2050	1990-2021	2021-2050
Global	4.38 (4.36 to 4.41)	2.74 (2.73 to 2.76)	3.01 (2.98 to 3.05)	2.10 (2.09 to 2.11)	1.50 (1.39 to 1.62)	1.52 (1.51 to 1.53)
SDI						
High SDI	3.16 (3.13 to 3.20)	1.60 (1.58 to 1.61)	2.53 (2.50 to 2.56)	1.50 (1.49 to 1.51)	0.94 (0.90 to 0.99)	0.99 (0.98 to 0.99)
High-middle SDI	3.35 (3.31 to 3.39)	1.96 (1.93 to 1.98)	2.96 (2.87 to 3.04)	1.99 (1.98 to 2.01)	1.70 (1.51 to 1.89)	1.61 (1.61 to 1.62)
Middle SDI	5.78 (5.74 to 5.82)	3.06 (3.03 to 3.08)	4.71 (4.67 to 4.75)	2.89 (2.87 to 2.91)	2.20 (2.10 to 2.30)	2.26 (2.25 to 2.27)
Low-middle SDI	4.48 (4.43 to 4.53)	3.36 (3.35 to 3.37)	2.54 (2.49 to 2.59)	2.49 (2.49 to 2.50)	1.04 (0.98 to 1.10)	1.18 (1.17 to 1.18)
Low SDI	3.38 (3.35 to 3.42)	4.34 (4.33 to 4.36)	0.65 (0.61 to 0.68)	2.31 (2.28 to 2.33)	0.78 (0.75 to 0.81)	0.79 (0.77 to 0.81)
GBD region						
East Asia	6.84 (6.72 to 6.96)	2.62 (2.60 to 2.63)	6.11 (6.06 to 6.17)	3.03 (3.02 to 3.04)	3.15 (3.03 to 3.26)	3.14 (3.13 to 3.16)
Southeast Asia	4.12 (4.07 to 4.17)	3.64 (3.62 to 3.67)	2.86 (2.77 to 2.96)	3.16 (3.14 to 3.18)	0.91 (0.80 to 1.02)	0.89 (0.87 to 0.91)
Oceania	3.12 (3.07 to 3.17)	3.75 (3.74 to 3.77)	0.63 (0.58 to 0.68)	1.97 (1.96 to 1.98)	0.34 (0.17 to 0.52)	0.27 (0.24 to 0.31)
Central Asia	1.95 (1.82 to 2.07)	3.59 (3.56 to 3.62)	0.85 (0.72 to 0.99)	2.73 (2.71 to 2.76)	0.33 (0.24 to 0.41)	0.36 (0.36 to 0.37)
Central Europe	1.92 (1.89 to 1.96)	1.19 (1.17 to 1.20)	2.18 (2.14 to 2.22)	1.82 (1.79 to 1.84)	0.31 (0.25 to 0.37)	0.25 (0.24 to 0.25)
Eastern Europe	0.98 (0.88 to 1.08)	1.03 (1.00 to 1.06)	1.25 (1.16 to 1.34)	1.48 (1.45 to 1.52)	-0.06 (-0.24 to 0.11)	0.08 (0.07 to 0.10)
High-income Asia Pacific	2.71 (2.52 to 2.90)	1.19 (1.18 to 1.20)	2.49 (2.28 to 2.69)	1.70 (1.70 to 1.71)	-0.04 (-0.26 to 0.17)	0.19 (0.18 to 0.21)
Australasia	3.66 (3.59 to 3.72)	2.09 (2.07 to 2.11)	2.37 (2.30 to 2.43)	1.25 (1.23 to 1.26)	0.92 (0.65 to 1.19)	1.06 (1.06 to 1.07)
Western Europe	2.57 (2.50 to 2.63)	1.54 (1.53 to 1.55)	2.14 (2.11 to 2.17)	1.51 (1.50 to 1.52)	0.80 (0.74 to 0.85)	0.64 (0.63 to 0.65)
Southern Latin America	2.90 (2.70 to 3.10)	2.56 (2.54 to 2.57)	1.83 (1.63 to 2.03)	2.08 (2.07 to 2.09)	0.54 (0.44 to 0.65)	0.62 (0.59 to 0.65)

High-income North America	3.00 (2.95 to 3.04)	1.69 (1.66 to 1.72)	2.07 (2.03 to 2.12)	1.37 (1.34 to 1.39)	0.92 (0.78 to 1.06)	0.85 (0.84 to 0.86)
Caribbean	3.42 (3.33 to 3.51)	2.79 (2.78 to 2.80)	2.41 (2.34 to 2.47)	2.64 (2.64 to 2.65)	0.83 (0.73 to 0.93)	0.90 (0.89 to 0.91)
Andean Latin America	5.54 (5.48 to 5.59)	3.25 (3.25 to 3.26)	3.68 (3.62 to 3.75)	2.15 (2.14 to 2.15)	1.75 (1.62 to 1.88)	1.77 (1.76 to 1.78)
Central Latin America	5.11 (5.06 to 5.16)	3.32 (3.31 to 3.33)	3.34 (3.06 to 3.63)	2.59 (2.58 to 2.59)	1.04 (0.84 to 1.24)	1.11 (1.10 to 1.12)
Tropical Latin America	4.44 (4.33 to 4.55)	3.06 (3.04 to 3.07)	3.16 (2.91 to 3.40)	2.79 (2.78 to 2.80)	0.79 (0.63 to 0.95)	0.81 (0.79 to 0.82)
North Africa and Middle East	7.54 (6.66 to 8.43)	4.56 (4.54 to 4.58)	2.74 (2.69 to 2.79)	3.34 (3.33 to 3.35)	1.33 (1.12 to 1.54)	1.38 (1.37 to 1.38)
South Asia	7.44 (6.45 to 8.43)	3.64 (3.64 to 3.65)	2.68 (2.60 to 2.75)	3.17 (3.17 to 3.17)	1.01 (0.93 to 1.10)	1.27 (1.26 to 1.29)
Central Sub-Saharan Africa	3.56 (3.50 to 3.62)	4.52 (4.51 to 4.53)	0.58 (0.49 to 0.66)	2.37 (2.36 to 2.38)	0.56 (0.38 to 0.73)	0.52 (0.50 to 0.55)
Eastern Sub-Saharan Africa	3.35 (3.30 to 3.39)	4.77 (4.76 to 4.78)	0.55 (0.51 to 0.58)	2.58 (2.56 to 2.60)	0.49 (0.44 to 0.53)	0.49 (0.49 to 0.50)
Southern Sub-Saharan Africa	3.23 (3.17 to 3.28)	3.48 (3.47 to 3.48)	1.72 (1.69 to 1.75)	2.37 (2.36 to 2.38)	0.49 (0.35 to 0.63)	0.64 (0.63 to 0.65)
Western Sub-Saharan Africa	3.36 (3.15 to 3.57)	4.99 (4.98 to 5.00)	0.29 (0.11 to 0.47)	2.45 (2.44 to 2.46)	0.70 (0.57 to 0.84)	0.65 (0.63 to 0.67)

Table S4. Projection for cases number, all-age prevalence and age-standardized prevalence of PD in 2021 and 2050 by 195 countries and territories (95% uncertainty interval).

Location	Number of cases (thousands)			All-age prevalence			Age-standardized prevalence		
	2021	2050	Percentage change (%)	2021	2050	Percentage change (%)	2021	2050	Percentage change (%)
Afghanistan	8 (6 to 10)	30 (24 to 37)	278 (199 to 405)	22 (18 to 28)	37 (30 to 46)	67 (36 to 122)	80 (60 to 101)	102 (72 to 140)	28 (23 to 35)
Albania	5 (4 to 6)	7 (6 to 9)	49 (37 to 91)	171 (140 to 211)	261 (216 to 335)	53 (21 to 95)	101 (72 to 127)	107 (75 to 147)	6 (1 to 12)
Algeria	33 (26 to 40)	108 (91 to 137)	226 (171 to 335)	77 (61 to 94)	178 (153 to 228)	131 (116 to 228)	96 (71 to 124)	123 (85 to 175)	28 (19 to 37)
American Samoa	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	106 (62 to 154)	52 (46 to 69)	77 (68 to 99)	47 (23 to 67)	78 (57 to 94)	80 (58 to 110)	4 (-2 to 9)
Andorra	0.2 (0.2 to 0.3)	0.5 (0.4 to 0.6)	129 (92 to 185)	265 (219 to 325)	697 (588 to 873)	163 (105 to 227)	141 (107 to 179)	179 (131 to 257)	27 (18 to 36)
Angola	6 (5 to 8)	23 (18 to 30)	264 (170 to 395)	20 (16 to 26)	38 (30 to 50)	87 (39 to 170)	63 (47 to 84)	77 (52 to 108)	21 (15 to 28)
Antigua and Barbuda	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.3)	141 (121 to 219)	107 (84 to 129)	253 (224 to 338)	136 (123 to 203)	85 (68 to 117)	115 (83 to 160)	35 (27 to 43)
Argentina	60 (53 to 75)	111 (102 to 145)	83 (57 to 126)	134 (119 to 167)	208 (193 to 274)	56 (37 to 109)	108 (79 to 136)	114 (85 to 156)	5 (0 to 11)

Armenia	3 (3 to 4)	5 (4 to 7)	55 (30 to 85)	112 (94 to 138)	187 (155 to 237)	67 (35 to 103)	79 (60 to 101)	82 (60 to 109)	4 (-2 to 10)
Australia	43 (34 to 51)	76 (65 to 95)	79 (46 to 127)	171 (140 to 206)	238 (204 to 296)	39 (18 to 69)	90 (70 to 119)	123 (88 to 171)	37 (29 to 45)
Austria	30 (24 to 36)	50 (40 to 61)	66 (27 to 87)	344 (271 to 412)	577 (458 to 696)	68 (32 to 103)	147 (103 to 192)	194 (127 to 273)	32 (22 to 42)
Azerbaijan	7 (6 to 9)	18 (15 to 23)	145 (139 to 216)	70 (55 to 86)	158 (129 to 201)	126 (101 to 213)	89 (65 to 116)	100 (70 to 145)	12 (6 to 19)
Bahamas	0.3 (0.3 to 0.4)	1 (0.6 to 1)	132 (101 to 211)	84 (67 to 101)	183 (153 to 231)	117 (82 to 186)	78 (62 to 102)	92 (69 to 121)	18 (11 to 25)
Bahrain	1 (1 to 1)	7 (6 to 9)	603 (571 to 951)	67 (50 to 81)	340 (291 to 423)	405 (343 to 571)	114 (89 to 152)	168 (124 to 234)	47 (41 to 53)
Bangladesh	110 (87 to 136)	288 (242 to 372)	162 (126 to 207)	69 (55 to 86)	170 (143 to 220)	148 (122 to 243)	85 (65 to 111)	106 (78 to 151)	25 (18 to 34)
Barbados	0.4 (0.3 to 0.5)	0.7 (0.6 to 0.9)	72 (54 to 152)	142 (113 to 171)	258 (215 to 330)	81 (52 to 146)	81 (63 to 105)	99 (72 to 136)	23 (17 to 29)
Belarus	17 (15 to 21)	23 (21 to 29)	30 (20 to 49)	187 (157 to 225)	283 (256 to 361)	51 (43 to 84)	103 (80 to 132)	106 (76 to 143)	3 (-1 to 8)
Belgium	37 (31 to 45)	59 (52 to 72)	60 (37 to 92)	320 (270 to 392)	453 (402 to 554)	41 (27 to 92)	144 (110 to 179)	195 (145 to 260)	36 (27 to 45)
Belize	0.2 (0.2 to 0.3)	0.7 (0.6 to 0.9)	229 (182 to 340)	52 (41 to 63)	124 (104 to 160)	139 (101 to 227)	75 (58 to 97)	92 (67 to 127)	22 (15 to 30)
Benin	3 (2.5 to 3.9)	12 (9.4 to 14.6)	280 (179 to 356)	25 (21 to 32)	50 (40 to 62)	101 (60 to 148)	74 (53 to 94)	82 (59 to 118)	12 (4 to 20)
Bermuda	0.1 (0.1 to 0.2)	0.2 (0.2 to 0.3)	69 (39 to 134)	205 (167 to 245)	389 (338 to 501)	90 (74 to 136)	93 (74 to 119)	104 (78 to 136)	12 (8 to 16)

Bhutan	0.6 (0.5 to 0.7)	2 (1.6 to 2.5)	242 (227 to 333)	60 (51 to 78)	173 (134 to 209)	188 (118 to 220)	94 (68 to 124)	143 (97 to 204)	53 (41 to 66)
Bolivia (Plurinational State of)	15 (12 to 18)	35 (29 to 44)	141 (101 to 202)	121 (98 to 151)	192 (159 to 240)	59 (43 to 107)	162 (122 to 209)	270 (194 to 369)	67 (60 to 75)
Bosnia and Herzegovina	6 (5 to 8)	8 (7 to 11)	27 (3 to 59)	190 (162 to 240)	294 (254 to 394)	55 (33 to 99)	100 (72 to 129)	100 (68 to 139)	0 (-6 to 7)
Botswana	1 (0.7 to 1.1)	3 (2.7 to 4.2)	246 (216 to 396)	39 (29 to 47)	100 (84 to 131)	155 (101 to 224)	70 (53 to 93)	91 (61 to 127)	30 (23 to 39)
Brazil	226 (176 to 272)	524 (427 to 659)	132 (115 to 202)	105 (82 to 127)	226 (184 to 284)	116 (87 to 175)	88 (70 to 116)	111 (83 to 156)	26 (18 to 33)
Brunei Darussalam	0.3 (0.2 to 0.3)	1 (1 to 1.4)	264 (260 to 396)	67 (53 to 79)	210 (183 to 271)	212 (229 to 325)	96 (73 to 129)	121 (83 to 166)	26 (17 to 35)
Bulgaria	16 (13 to 19)	13 (10 to 16)	-21 (-32 to 0)	232 (188 to 275)	247 (202 to 321)	7 (-5 to 32)	94 (73 to 122)	68 (47 to 88)	-28 (-32 to -23)
Burkina Faso	5 (4 to 7)	17 (14 to 22)	213 (170 to 286)	24 (20 to 30)	35 (29 to 46)	48 (26 to 84)	69 (52 to 89)	78 (56 to 105)	12 (6 to 19)
Burundi	2 (1.7 to 2.7)	7 (5.3 to 8.5)	224 (198 to 349)	18 (14 to 23)	27 (21 to 34)	49 (7 to 85)	56 (42 to 73)	62 (44 to 88)	11 (6 to 16)
Cabo Verde	0.4 (0.3 to 0.5)	1 (1 to 1.6)	235 (161 to 307)	68 (55 to 84)	189 (154 to 244)	179 (165 to 241)	84 (63 to 107)	120 (84 to 168)	43 (34 to 52)
Cambodia	8 (7 to 10)	23 (20 to 29)	177 (134 to 260)	49 (41 to 63)	112 (96 to 144)	127 (74 to 161)	74 (57 to 94)	100 (70 to 136)	34 (25 to 44)
Cameroon	8 (6 to 10)	26 (22 to 34)	224 (167 to 296)	27 (22 to 34)	57 (49 to 76)	111 (98 to 174)	79 (58 to 101)	89 (63 to 123)	12 (6 to 19)
Canada	153 (137 to 171)	259 (243 to 298)	69 (55 to 104)	414 (374 to 466)	600 (564 to 692)	45 (32 to 72)	197 (167 to 230)	296 (249 to 352)	50 (45 to 56)

Central African Republic	1 (0.8 to 1.3)	2 (1.9 to 2.9)	119 (77 to 192)	22 (17 to 28)	45 (38 to 59)	104 (75 to 178)	58 (43 to 74)	64 (43 to 87)	10 (1 to 20)
Chad	3 (2.6 to 4)	11 (9 to 14)	234 (163 to 323)	19 (16 to 25)	22 (19 to 30)	19 (0 to 49)	66 (47 to 85)	78 (53 to 110)	19 (12 to 26)
Chile	31 (26 to 37)	70 (62 to 86)	126 (102 to 172)	171 (145 to 204)	350 (308 to 430)	105 (87 to 159)	119 (91 to 152)	172 (120 to 232)	44 (38 to 51)
China	5091 (4137 to 6122)	10516 (9235 to 12921)	107 (71 to 125)	360 (293 to 434)	831 (724 to 1014)	131 (98 to 183)	242 (190 to 315)	583 (449 to 822)	141 (126 to 157)
Colombia	60 (45 to 69)	149 (123 to 188)	147 (107 to 230)	116 (90 to 136)	245 (202 to 309)	111 (86 to 185)	93 (74 to 123)	126 (91 to 171)	36 (31 to 41)
Comoros	0.3 (0.2 to 0.3)	0.7 (0.5 to 0.9)	155 (103 to 196)	36 (29 to 46)	71 (56 to 90)	98 (46 to 158)	61 (44 to 81)	73 (47 to 104)	20 (13 to 28)
Congo	2 (1.3 to 2)	5 (4 to 7)	215 (155 to 333)	31 (25 to 40)	77 (65 to 101)	146 (127 to 182)	72 (53 to 93)	84 (58 to 119)	18 (12 to 23)
Costa Rica	6 (5 to 7)	15 (12 to 18)	151 (106 to 232)	124 (99 to 149)	274 (219 to 329)	121 (96 to 182)	106 (83 to 143)	140 (100 to 196)	33 (26 to 40)
Côte d'Ivoire	7 (6 to 8)	27 (24 to 35)	298 (240 to 411)	26 (21 to 32)	58 (51 to 74)	51 (88 to 189)	78 (58 to 99)	90 (65 to 123)	15 (9 to 21)
Croatia	10 (8 to 12)	11 (10 to 15)	17 (-12 to 45)	235 (199 to 285)	355 (296 to 453)	134 (21 to 90)	99 (73 to 129)	105 (74 to 147)	5 (0 to 12)
Cuba	15 (12 to 18)	29 (26 to 39)	96 (84 to 139)	134 (108 to 158)	313 (274 to 416)	87 (99 to 223)	73 (59 to 93)	103 (76 to 136)	41 (36 to 47)
Cyprus	3 (2.7 to 4.2)	7 (6 to 10)	93 (73 to 199)	263 (214 to 323)	490 (462 to 716)	49 (98 to 169)	151 (113 to 202)	172 (122 to 253)	14 (6 to 22)
Czechia	23 (20 to 27)	31 (29 to 39)	36 (21 to 64)	215 (186 to 258)	320 (298 to 409)	126 (33 to 82)	96 (74 to 121)	108 (81 to 146)	13 (8 to 18)

Democratic People's Republic of Korea	52 (42 to 62)	90 (77 to 116)	73 (52 to 135)	203 (162 to 244)	385 (325 to 495)	89 (68 to 154)	160 (119 to 209)	307 (218 to 436)	92 (82 to 101)
Democratic Republic of the Congo	19 (15 to 24)	46 (36 to 61)	145 (96 to 208)	21 (17 to 28)	28 (22 to 37)	29 (8 to 46)	60 (43 to 77)	67 (45 to 94)	12 (5 to 20)
Denmark	18 (15 to 22)	26 (21 to 32)	45 (24 to 81)	305 (255 to 380)	415 (347 to 522)	36 (14 to 61)	139 (98 to 180)	228 (160 to 329)	64 (54 to 74)
Djibouti	0.3 (0.3 to 0.4)	1 (0.9 to 1.5)	246 (198 to 342)	27 (21 to 34)	73 (61 to 96)	166 (133 to 252)	60 (46 to 78)	73 (52 to 101)	21 (11 to 32)
Dominica	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	55 (33 to 84)	106 (86 to 130)	169 (138 to 210)	59 (35 to 93)	75 (58 to 96)	90 (66 to 119)	20 (13 to 28)
Dominican Republic	7 (6 to 9)	17 (14 to 21)	131 (95 to 200)	68 (53 to 81)	141 (119 to 178)	107 (67 to 147)	73 (57 to 94)	96 (68 to 130)	31 (23 to 40)
Ecuador	25 (20 to 30)	59 (49 to 72)	135 (114 to 198)	145 (116 to 173)	275 (229 to 338)	90 (63 to 153)	153 (115 to 199)	259 (185 to 361)	70 (62 to 78)
Egypt	70 (58 to 85)	236 (214 to 313)	236 (196 to 357)	69 (59 to 85)	160 (146 to 213)	130 (102 to 182)	133 (105 to 170)	204 (146 to 282)	54 (43 to 66)
El Salvador	6 (5 to 7)	12 (10 to 15)	97 (77 to 150)	100 (81 to 119)	213 (185 to 260)	114 (77 to 151)	94 (77 to 125)	132 (99 to 179)	41 (31 to 51)
Equatorial Guinea	0.4 (0.3 to 0.4)	2 (1.3 to 2.1)	374 (255 to 563)	24 (19 to 30)	66 (52 to 82)	176 (127 to 248)	78 (57 to 101)	116 (83 to 167)	48 (39 to 58)
Eritrea	1 (0.9 to 1.5)	4 (3 to 5)	234 (173 to 292)	19 (15 to 25)	46 (37 to 60)	137 (104 to 194)	57 (44 to 74)	65 (48 to 90)	13 (5 to 22)
Estonia	3 (3 to 4)	3 (3 to 4)	14 (-3 to 50)	233 (195 to 281)	298 (268 to 376)	28 (12 to 72)	102 (80 to 130)	98 (71 to 132)	-4 (-9 to 1)
Eswatini	0.4 (0.3 to 0.4)	1 (0.8 to 1.2)	157 (122 to 241)	31 (25 to 38)	58 (48 to 76)	87 (74 to 156)	68 (51 to 89)	79 (56 to 109)	16 (11 to 22)

Ethiopia	24 (19 to 29)	86 (68 to 107)	254 (163 to 358)	22 (17 to 27)	42 (34 to 54)	97 (59 to 134)	60 (46 to 79)	70 (50 to 96)	16 (7 to 25)
Fiji	0.6 (0.5 to 0.8)	1 (1 to 1.5)	91 (56 to 127)	67 (54 to 84)	109 (89 to 137)	63 (38 to 112)	92 (64 to 120)	95 (64 to 136)	3 (-5 to 12)
Finland	21 (18 to 25)	28 (24 to 36)	31 (37 to 83)	385 (318 to 461)	493 (433 to 642)	28 (13 to 77)	150 (116 to 203)	239 (175 to 332)	59 (50 to 69)
France	241 (188 to 286)	356 (276 to 443)	48 (24 to 84)	366 (286 to 435)	510 (395 to 635)	39 (11 to 81)	145 (108 to 194)	199 (139 to 279)	37 (30 to 45)
Gabon	1 (0.6 to 1)	2 (1.9 to 2.9)	186 (154 to 274)	45 (36 to 57)	97 (82 to 124)	114 (76 to 157)	80 (61 to 104)	96 (69 to 133)	20 (14 to 27)
Gambia	0.7 (0.5 to 0.8)	2 (1.7 to 2.7)	225 (150 to 302)	29 (24 to 37)	59 (49 to 77)	105 (68 to 151)	77 (56 to 100)	99 (68 to 138)	28 (21 to 36)
Georgia	4 (5 to 7)	5 (4 to 6)	8 (-29 to 13)	125 (104 to 154)	146 (122 to 189)	17 (8 to 60)	75 (59 to 94)	66 (49 to 88)	-12 (-17 to -7)
Germany	414 (395 to 468)	574 (548 to 649)	38 (27 to 53)	498 (474 to 561)	695 (662 to 784)	39 (33 to 52)	188 (162 to 213)	335 (290 to 398)	78 (73 to 82)
Ghana	9 (8 to 12)	32 (28 to 43)	239 (185 to 318)	30 (25 to 38)	67 (58 to 89)	125 (120 to 191)	69 (52 to 90)	86 (60 to 120)	24 (17 to 32)
Greece	38 (32 to 45)	52 (45 to 66)	38 (20 to 62)	371 (316 to 441)	590 (498 to 734)	59 (47 to 90)	137 (106 to 180)	167 (115 to 228)	21 (15 to 28)
Greenland	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	103 (95 to 175)	139 (112 to 168)	271 (249 to 352)	96 (74 to 165)	117 (87 to 150)	143 (100 to 196)	23 (15 to 31)
Grenada	0.1 (0.1 to 0.1)	0.2 (0.2 to 0.2)	53 (47 to 114)	112 (83 to 129)	173 (144 to 228)	54 (38 to 122)	75 (58 to 98)	98 (69 to 134)	30 (24 to 37)
Guam	0.2 (0.2 to 0.2)	0.3 (0.3 to 0.4)	83 (39 to 140)	106 (93 to 135)	162 (143 to 219)	52 (27 to 104)	102 (76 to 135)	104 (71 to 143)	2 (-6 to 9)

Guatemala	10 (8 to 12)	31 (25 to 39)	213 (142 to 304)	56 (43 to 67)	128 (102 to 164)	130 (85 to 189)	82 (63 to 111)	103 (74 to 148)	26 (20 to 32)
Guinea	3 (2.8 to 4.4)	9 (8 to 12)	170 (112 to 262)	27 (23 to 35)	41 (34 to 53)	53 (22 to 79)	73 (53 to 91)	86 (59 to 115)	18 (13 to 24)
Guinea-Bissau	0.4 (0.3 to 0.5)	1.5 (1.1 to 1.9)	246 (151 to 337)	21 (17 to 28)	45 (35 to 60)	110 (75 to 150)	71 (53 to 94)	82 (54 to 118)	14 (9 to 20)
Guyana	0.4 (0.3 to 0.5)	1 (0.8 to 1.2)	106 (67 to 139)	58 (46 to 70)	109 (96 to 145)	88 (77 to 127)	68 (54 to 88)	80 (57 to 105)	17 (13 to 22)
Haiti	4 (3 to 5)	11 (10 to 15)	157 (101 to 254)	36 (29 to 45)	72 (61 to 94)	99 (68 to 163)	64 (50 to 81)	73 (55 to 99)	14 (8 to 22)
Honduras	7 (5 to 9)	24 (19 to 32)	238 (197 to 410)	72 (55 to 87)	168 (133 to 219)	133 (81 to 212)	110 (85 to 150)	171 (117 to 236)	55 (45 to 66)
Hungary	18 (15 to 22)	23 (20 to 28)	26 (10 to 65)	191 (161 to 231)	284 (249 to 348)	49 (40 to 93)	87 (67 to 108)	101 (75 to 132)	16 (11 to 21)
Iceland	1 (0.8 to 1.3)	2 (1.7 to 2.6)	91 (59 to 148)	306 (247 to 369)	511 (443 to 651)	67 (46 to 139)	170 (129 to 225)	235 (164 to 329)	38 (29 to 47)
India	1033 (836 to 1266)	2765 (2337 to 3540)	168 (126 to 237)	73 (60 to 91)	174 (147 to 223)	138 (98 to 183)	93 (71 to 121)	135 (98 to 188)	45 (38 to 52)
Indonesia	164 (131 to 200)	465 (413 to 596)	184 (163 to 301)	62 (50 to 77)	157 (139 to 201)	152 (125 to 239)	81 (60 to 103)	105 (75 to 145)	30 (23 to 38)
Iran (Islamic Republic of)	74 (58 to 87)	237 (196 to 286)	222 (197 to 326)	87 (69 to 104)	251 (208 to 303)	187 (144 to 282)	101 (79 to 134)	144 (103 to 201)	43 (38 to 49)
Iraq	23 (18 to 27)	107 (82 to 128)	355 (268 to 453)	50 (40 to 61)	133 (104 to 162)	165 (109 to 204)	98 (71 to 127)	155 (109 to 217)	59 (47 to 71)
Ireland	13 (11 to 15)	27 (23 to 33)	109 (67 to 160)	259 (215 to 309)	471 (399 to 580)	82 (54 to 131)	150 (117 to 192)	211 (156 to 284)	40 (32 to 48)

Israel	26 (21 to 30)	52 (44 to 66)	99 (63 to 152)	279 (224 to 325)	370 (318 to 472)	33 (24 to 71)	196 (152 to 263)	215 (153 to 298)	10 (3 to 17)
Italy	190 (158 to 237)	170 (131 to 241)	-10 (-27 to 3)	318 (265 to 396)	328 (251 to 460)	3 (-25 to 34)	112 (86 to 144)	69 (50 to 95)	-39 (-41 to -36)
Jamaica	2 (1.8 to 2.8)	4 (4 to 6)	99 (74 to 159)	82 (65 to 100)	185 (151 to 246)	125 (107 to 200)	73 (57 to 97)	91 (65 to 123)	24 (15 to 33)
Japan	202 (183 to 274)	219 (176 to 290)	8 (-26 to 21)	161 (145 to 217)	214 (170 to 281)	33 (2 to 46)	59 (41 to 68)	55 (39 to 72)	-7 (-10 to -4)
Jordan	5 (3.6 to 5.3)	20 (17 to 25)	349 (316 to 501)	40 (32 to 47)	115 (100 to 141)	188 (158 to 242)	74 (60 to 94)	100 (77 to 130)	35 (30 to 39)
Kazakhstan	15 (13 to 19)	39 (35 to 50)	153 (118 to 207)	84 (72 to 105)	165 (147 to 210)	96 (74 to 135)	94 (73 to 117)	116 (85 to 153)	23 (15 to 30)
Kenya	13 (10 to 16)	43 (35 to 55)	233 (193 to 342)	25 (20 to 31)	55 (46 to 72)	123 (76 to 212)	62 (48 to 80)	71 (52 to 97)	14 (9 to 20)
Kiribati	0.1 (0 to 0.1)	0.1 (0.1 to 0.1)	114 (104 to 210)	40 (34 to 51)	52 (47 to 71)	30 (14 to 51)	89 (65 to 113)	97 (68 to 136)	10 (4 to 15)
Kuwait	3 (1.9 to 3)	17 (14 to 20)	555 (448 to 708)	57 (43 to 67)	299 (255 to 366)	425 (389 to 549)	95 (70 to 127)	122 (85 to 173)	28 (19 to 38)
Kyrgyzstan	3 (2.4 to 3.7)	8 (7 to 10)	164 (143 to 253)	44 (38 to 57)	84 (76 to 108)	90 (69 to 123)	72 (53 to 90)	71 (51 to 95)	-1 (-7 to 5)
Lao People's Democratic Republic	3 (2.3 to 3.7)	9 (8 to 12)	211 (147 to 289)	42 (33 to 51)	104 (86 to 132)	148 (106 to 215)	74 (57 to 97)	91 (64 to 125)	22 (13 to 32)
Latvia	4 (4 to 5)	4 (4 to 5)	-4 (-11 to 19)	220 (193 to 278)	316 (282 to 417)	43 (22 to 87)	97 (73 to 124)	90 (65 to 123)	-8 (-12 to -4)
Lebanon	6 (5 to 7)	18 (15 to 23)	211 (203 to 321)	66 (63 to 94)	159 (130 to 202)	143 (71 to 149)	93 (70 to 121)	128 (95 to 180)	38 (29 to 47)

Lesotho	0.6 (0.5 to 0.8)	1 (1 to 1.6)	86 (67 to 155)	32 (25 to 40)	48 (40 to 64)	50 (30 to 96)	60 (46 to 78)	74 (53 to 101)	25 (21 to 28)
Liberia	1 (1 to 1.5)	4 (3 to 5)	203 (169 to 262)	24 (20 to 31)	47 (41 to 60)	92 (64 to 136)	69 (51 to 88)	77 (54 to 110)	12 (5 to 19)
Libya	4 (3 to 5)	8 (6 to 10)	88 (45 to 153)	58 (49 to 74)	88 (73 to 117)	51 (37 to 101)	92 (70 to 116)	135 (98 to 179)	47 (40 to 54)
Lithuania	6 (5 to 7)	6 (5 to 8)	3 (-12 to 39)	207 (171 to 251)	263 (218 to 334)	27 (8 to 41)	91 (71 to 116)	87 (64 to 116)	-4 (-9 to 2)
Luxembourg	2 (1.4 to 2.1)	4 (3 to 5)	111 (84 to 184)	279 (226 to 341)	482 (418 to 622)	73 (54 to 124)	158 (118 to 202)	224 (157 to 309)	41 (36 to 47)
Madagascar	5 (4 to 6)	17 (14 to 22)	236 (193 to 316)	18 (14 to 23)	28 (23 to 36)	59 (17 to 116)	53 (39 to 69)	61 (42 to 83)	15 (8 to 22)
Malawi	4 (3 to 5)	13 (10 to 17)	205 (132 to 354)	23 (18 to 29)	40 (32 to 52)	74 (33 to 122)	58 (43 to 74)	64 (46 to 90)	10 (4 to 17)
Malaysia	24 (19 to 30)	67 (55 to 87)	179 (131 to 237)	76 (61 to 94)	161 (133 to 211)	114 (68 to 154)	93 (69 to 125)	124 (87 to 181)	33 (23 to 43)
Maldives	0.3 (0 to 0)	1 (1 to 2)	350 (255 to 526)	59 (47 to 71)	198 (168 to 250)	234 (179 to 332)	95 (71 to 124)	118 (83 to 162)	23 (16 to 31)
Mali	5 (4 to 6)	15 (13 to 19)	211 (162 to 312)	22 (18 to 28)	30 (25 to 38)	35 (8 to 70)	65 (48 to 82)	72 (50 to 99)	11 (5 to 19)
Malta	2 (1.3 to 1.9)	2 (1.8 to 2.7)	38 (14 to 65)	353 (302 to 442)	513 (447 to 656)	45 (19 to 84)	156 (115 to 191)	208 (153 to 287)	34 (26 to 42)
Marshall Islands	0 (0 to 0)	0.1 (0.1 to 0.1)	163 (127 to 257)	47 (38 to 59)	93 (75 to 125)	99 (79 to 166)	102 (73 to 130)	117 (82 to 164)	15 (7 to 24)
Mauritania	1.4 (1.1 to 1.8)	5 (4 to 7)	248 (179 to 362)	34 (28 to 44)	67 (54 to 90)	99 (48 to 162)	77 (55 to 98)	88 (61 to 123)	15 (7 to 24)

Mauritius	2 (1.2 to 1.9)	3 (2.5 to 3.9)	91 (71 to 136)	123 (98 to 148)	250 (211 to 324)	102 (79 to 153)	88 (66 to 114)	106 (74 to 146)	21 (14 to 28)
Mexico	125 (97 to 146)	338 (286 to 436)	171 (152 to 243)	95 (76 to 114)	205 (174 to 265)	115 (96 to 184)	96 (78 to 130)	134 (99 to 179)	40 (33 to 47)
Micronesia (Federated States of)	0.1 (0 to 0.1)	0.1 (0.1 to 0.2)	135 (99 to 201)	53 (43 to 67)	92 (77 to 119)	71 (35 to 108)	94 (66 to 117)	107 (72 to 147)	14 (5 to 24)
Mongolia	1.4 (1.1 to 1.7)	4 (3 to 6)	213 (151 to 303)	41 (33 to 51)	96 (77 to 128)	138 (103 to 220)	70 (51 to 89)	71 (52 to 96)	2 (-4 to 8)
Montenegro	1 (0.9 to 1.3)	1 (1.2 to 1.8)	30 (5 to 54)	175 (144 to 216)	240 (207 to 307)	37 (20 to 77)	102 (76 to 126)	106 (75 to 141)	4 (-1 to 8)
Morocco	31 (25 to 37)	81 (68 to 100)	161 (123 to 210)	86 (69 to 104)	193 (161 to 239)	125 (74 to 197)	98 (72 to 124)	157 (112 to 222)	60 (48 to 73)
Mozambique	6 (4 to 7)	18 (15 to 24)	222 (162 to 344)	18 (14 to 23)	37 (30 to 48)	107 (71 to 155)	55 (42 to 74)	63 (43 to 90)	14 (8 to 21)
Myanmar	34 (27 to 41)	83 (69 to 100)	146 (121 to 190)	62 (50 to 77)	131 (110 to 159)	111 (73 to 136)	76 (57 to 96)	100 (74 to 141)	31 (25 to 39)
Namibia	1 (0.8 to 1.2)	3 (2 to 4)	201 (149 to 274)	40 (32 to 48)	79 (66 to 101)	101 (77 to 166)	69 (51 to 88)	87 (59 to 122)	27 (17 to 37)
Nepal	18 (15 to 22)	45 (36 to 55)	146 (85 to 204)	59 (48 to 74)	132 (106 to 163)	122 (55 to 181)	85 (63 to 109)	138 (92 to 187)	62 (53 to 73)
Netherlands	65 (54 to 76)	88 (79 to 108)	35 (29 to 69)	382 (316 to 448)	526 (472 to 646)	38 (25 to 66)	169 (136 to 211)	159 (122 to 205)	-6 (-10 to -1)
New Zealand	6 (5 to 7)	10 (8 to 13)	68 (32 to 116)	133 (107 to 163)	187 (156 to 238)	40 (38 to 100)	68 (51 to 91)	82 (55 to 113)	20 (14 to 27)
Nicaragua	6 (4 to 6)	16 (13 to 20)	195 (174 to 293)	84 (64 to 98)	210 (169 to 260)	149 (130 to 182)	108 (84 to 143)	141 (103 to 201)	30 (24 to 38)

Niger	4 (3 to 5)	14 (12 to 18)	243 (195 to 375)	17 (14 to 22)	20 (16 to 26)	13 (-16 to 52)	64 (46 to 82)	71 (49 to 100)	12 (6 to 19)
Nigeria	61 (49 to 74)	269 (213 to 335)	339 (237 to 394)	27 (22 to 34)	56 (45 to 71)	106 (71 to 159)	81 (59 to 102)	100 (70 to 139)	25 (16 to 33)
North Macedonia	4 (3 to 5)	6 (6 to 8)	64 (37 to 154)	179 (138 to 212)	317 (275 to 402)	77 (60 to 122)	102 (79 to 133)	116 (84 to 158)	14 (8 to 20)
Northern Mariana Islands	0.1 (0 to 0.1)	0.1 (0.1 to 0.2)	128 (112 to 221)	121 (93 to 142)	257 (235 to 333)	112 (114 to 204)	111 (83 to 139)	111 (80 to 148)	0 (-6 to 6)
Norway	10 (8 to 12)	18 (14 to 21)	76 (52 to 92)	188 (154 to 226)	269 (213 to 314)	43 (16 to 89)	98 (73 to 125)	383 (284 to 547)	292 (273 to 311)
Oman	3 (1.8 to 2.9)	19 (16 to 24)	633 (577 to 919)	53 (38 to 61)	244 (198 to 303)	357 (328 to 551)	138 (98 to 176)	222 (158 to 315)	60 (51 to 70)
Pakistan	94 (73 to 113)	288 (229 to 350)	207 (161 to 290)	42 (33 to 51)	95 (76 to 116)	127 (88 to 198)	90 (68 to 116)	118 (83 to 162)	31 (23 to 39)
Palestine	2 (1.8 to 2.8)	9 (7 to 11)	270 (248 to 409)	47 (36 to 56)	109 (88 to 135)	132 (111 to 210)	99 (77 to 129)	139 (105 to 193)	40 (32 to 49)
Panama	5 (4 to 6)	12 (10 to 15)	147 (121 to 223)	119 (90 to 138)	213 (176 to 261)	78 (63 to 134)	103 (83 to 139)	141 (104 to 196)	38 (30 to 45)
Papua New Guinea	3 (2 to 4)	8 (6 to 10)	179 (117 to 264)	28 (24 to 36)	44 (36 to 57)	61 (17 to 100)	79 (57 to 100)	86 (61 to 124)	9 (3 to 15)
Paraguay	5 (4 to 6)	13 (10 to 16)	155 (121 to 206)	70 (56 to 86)	142 (115 to 175)	102 (61 to 183)	86 (68 to 111)	108 (80 to 148)	26 (19 to 34)
Peru	56 (45 to 67)	141 (118 to 176)	152 (116 to 215)	160 (133 to 197)	290 (245 to 366)	81 (54 to 116)	162 (124 to 209)	275 (199 to 376)	69 (60 to 80)
Philippines	51 (43 to 65)	113 (90 to 144)	119 (72 to 186)	48 (40 to 60)	75 (61 to 97)	57 (27 to 94)	76 (57 to 97)	83 (60 to 114)	11 (5 to 17)

Poland	80 (70 to 93)	100 (92 to 121)	24 (17 to 48)	212 (185 to 246)	314 (289 to 379)	48 (50 to 74)	104 (85 to 127)	118 (91 to 151)	14 (10 to 18)
Portugal	31 (25 to 37)	48 (39 to 59)	56 (25 to 81)	293 (242 to 355)	551 (447 to 680)	88 (55 to 132)	112 (83 to 145)	155 (113 to 216)	38 (30 to 47)
Puerto Rico	6 (5 to 8)	10 (8 to 12)	49 (42 to 99)	179 (142 to 217)	332 (269 to 428)	86 (53 to 132)	81 (62 to 104)	97 (69 to 132)	19 (12 to 26)
Qatar	1 (0.9 to 1.5)	18 (15 to 23)	1308 (1206 to 2020)	45 (31 to 52)	520 (434 to 648)	1062 (945 to 1726)	160 (117 to 217)	259 (175 to 378)	62 (48 to 76)
Republic of Korea	88 (69 to 104)	218 (189 to 275)	149 (112 to 198)	166 (130 to 196)	439 (378 to 549)	165 (141 to 259)	87 (67 to 113)	145 (104 to 198)	65 (54 to 77)
Republic of Moldova	5 (4 to 6)	7 (6 to 9)	53 (35 to 105)	131 (105 to 159)	244 (211 to 314)	87 (58 to 172)	79 (59 to 102)	65 (46 to 88)	-17 (-22 to -12)
Romania	36 (30 to 44)	47 (41 to 60)	30 (8 to 70)	191 (160 to 231)	314 (271 to 402)	65 (39 to 94)	87 (68 to 109)	98 (73 to 130)	13 (8 to 19)
Russian Federation	224 (181 to 273)	304 (269 to 409)	35 (28 to 83)	155 (125 to 189)	229 (202 to 307)	47 (39 to 98)	90 (69 to 117)	92 (65 to 124)	2 (-4 to 10)
Rwanda	3 (2 to 4)	11 (9 to 14)	253 (192 to 370)	23 (19 to 30)	45 (36 to 59)	92 (60 to 158)	57 (42 to 75)	64 (45 to 91)	12 (6 to 19)
Saint Lucia	0.2 (0.1 to 0.2)	0.4 (0.3 to 0.5)	114 (72 to 138)	101 (80 to 124)	210 (166 to 265)	108 (66 to 180)	78 (60 to 102)	91 (65 to 122)	17 (11 to 23)
Saint Vincent and the Grenadines	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	63 (37 to 127)	91 (72 to 110)	171 (147 to 215)	87 (48 to 131)	71 (54 to 91)	87 (61 to 118)	23 (16 to 29)
Samoa	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.3)	101 (59 to 156)	59 (51 to 76)	69 (58 to 89)	16 (-15 to 44)	98 (72 to 123)	111 (79 to 150)	13 (7 to 20)
Sao Tome and Principe	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.3)	225 (168 to 298)	38 (31 to 49)	96 (75 to 122)	149 (109 to 186)	87 (64 to 112)	114 (78 to 159)	31 (25 to 39)

Saudi Arabia	20 (14 to 23)	127 (101 to 159)	536 (438 to 876)	55 (40 to 65)	287 (229 to 359)	419 (347 to 575)	133 (101 to 178)	216 (152 to 311)	63 (50 to 76)
Senegal	5 (4 to 7)	17 (14 to 23)	223 (178 to 287)	33 (28 to 42)	61 (51 to 83)	85 (56 to 107)	79 (59 to 103)	95 (66 to 132)	20 (15 to 26)
Serbia	16 (14 to 20)	18 (14 to 22)	11 (-21 to 32)	184 (157 to 228)	245 (189 to 298)	34 (2 to 59)	93 (68 to 120)	106 (74 to 141)	14 (8 to 20)
Seychelles	0.1 (0.1 to 0.1)	0.3 (0.2 to 0.4)	143 (87 to 260)	111 (89 to 137)	254 (211 to 328)	130 (102 to 177)	108 (81 to 137)	133 (94 to 174)	24 (15 to 33)
Sierra Leone	2 (1.7 to 2.6)	6 (5 to 9)	212 (168 to 295)	24 (20 to 32)	49 (42 to 66)	100 (58 to 169)	65 (50 to 84)	75 (54 to 101)	14 (9 to 20)
Singapore	6 (5 to 8)	21 (17 to 27)	225 (150 to 330)	109 (88 to 132)	269 (223 to 341)	146 (97 to 203)	79 (62 to 105)	104 (77 to 147)	31 (24 to 39)
Slovakia	9 (7 to 11)	13 (11 to 16)	48 (23 to 105)	159 (132 to 197)	271 (243 to 351)	70 (42 to 105)	87 (65 to 110)	91 (66 to 123)	5 (-1 to 10)
Slovenia	5 (4 to 6)	6 (6 to 8)	30 (20 to 75)	238 (196 to 290)	349 (318 to 457)	47 (27 to 72)	102 (76 to 127)	107 (75 to 141)	4 (-3 to 12)
Solomon Islands	0.3 (0.2 to 0.3)	0.6 (0.5 to 0.8)	149 (103 to 191)	37 (30 to 46)	60 (51 to 79)	63 (45 to 129)	89 (63 to 113)	95 (66 to 137)	6 (-1 to 14)
Somalia	3 (2 to 4)	8 (6 to 10)	160 (92 to 234)	16 (12 to 20)	20 (15 to 26)	27 (0 to 68)	50 (37 to 66)	52 (36 to 74)	5 (-1 to 12)
South Africa	30 (23 to 36)	71 (60 to 91)	136 (92 to 230)	53 (41 to 65)	97 (82 to 125)	84 (51 to 111)	67 (52 to 88)	83 (58 to 115)	23 (17 to 28)
South Sudan	2 (1.5 to 2.3)	7 (5 to 8)	263 (229 to 342)	17 (14 to 23)	25 (19 to 32)	48 (7 to 51)	54 (39 to 71)	58 (40 to 84)	7 (1 to 13)
Spain	200 (169 to 241)	351 (304 to 435)	76 (51 to 103)	434 (369 to 525)	848 (728 to 1043)	95 (65 to 132)	178 (133 to 227)	207 (147 to 279)	16 (7 to 25)

Sri Lanka	25 (20 to 30)	53 (44 to 68)	114 (81 to 157)	115 (92 to 141)	257 (210 to 325)	123 (95 to 184)	95 (68 to 124)	124 (85 to 172)	31 (22 to 41)
Sudan	16 (12 to 20)	62 (48 to 78)	287 (188 to 376)	37 (30 to 47)	89 (70 to 113)	141 (93 to 194)	87 (66 to 118)	127 (87 to 185)	46 (35 to 57)
Suriname	0.4 (0.3 to 0.5)	1 (0.7 to 1)	100 (88 to 168)	69 (55 to 83)	123 (103 to 158)	77 (38 to 125)	64 (49 to 84)	84 (59 to 115)	32 (24 to 40)
Sweden	29 (24 to 35)	52 (46 to 66)	76 (55 to 126)	289 (239 to 347)	442 (391 to 563)	53 (37 to 96)	122 (93 to 160)	189 (137 to 272)	56 (47 to 64)
Switzerland	30 (24 to 36)	53 (45 to 67)	77 (45 to 131)	339 (277 to 416)	541 (459 to 686)	60 (33 to 107)	152 (111 to 192)	201 (144 to 277)	32 (24 to 41)
Syrian Arab Republic	12 (9 to 15)	43 (36 to 56)	259 (231 to 413)	67 (55 to 87)	218 (183 to 280)	226 (168 to 273)	97 (72 to 125)	148 (108 to 212)	53 (42 to 64)
Taiwan (Province of China)	83 (73 to 89)	170 (156 to 187)	104 (89 to 137)	354 (309 to 378)	815 (741 to 886)	130 (115 to 151)	186 (168 to 224)	630 (548 to 768)	240 (228 to 251)
Tajikistan	5 (3 to 5)	9 (7 to 14)	105 (69 to 241)	46 (36 to 56)	59 (47 to 93)	28 (3 to 80)	104 (75 to 135)	120 (84 to 180)	16 (9 to 24)
Thailand	100 (83 to 118)	246 (218 to 310)	146 (132 to 229)	141 (118 to 168)	374 (329 to 468)	164 (131 to 235)	91 (70 to 115)	108 (81 to 148)	19 (14 to 25)
Timor-Leste	0.6 (0.5 to 0.8)	2 (1.3 to 2)	152 (135 to 241)	46 (36 to 57)	71 (60 to 92)	57 (37 to 108)	74 (56 to 98)	94 (68 to 136)	27 (19 to 36)
Togo	2 (1.7 to 2.7)	7 (6 to 10)	253 (190 to 388)	26 (21 to 34)	64 (53 to 87)	143 (118 to 205)	69 (48 to 92)	82 (53 to 114)	18 (10 to 25)
Tonga	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	110 (86 to 174)	64 (55 to 84)	85 (72 to 109)	32 (9 to 53)	90 (66 to 114)	101 (72 to 140)	12 (6 to 19)
Trinidad and Tobago	1 (1 to 1.6)	3 (2.1 to 3.4)	91 (49 to 149)	96 (75 to 117)	188 (151 to 246)	95 (72 to 154)	68 (52 to 89)	82 (57 to 112)	21 (14 to 28)

Tunisia	12 (10 to 15)	33 (27 to 41)	169 (121 to 243)	104 (86 to 129)	244 (199 to 302)	134 (99 to 187)	96 (71 to 124)	139 (99 to 191)	44 (34 to 55)
Turkey	97 (74 to 116)	280 (218 to 341)	189 (173 to 246)	116 (90 to 141)	261 (204 to 319)	106 (88 to 153)	102 (74 to 131)	159 (109 to 218)	57 (42 to 142)
Turkmenistan	2 (2 to 3)	7 (6 to 8)	175 (136 to 253)	47 (39 to 59)	97 (83 to 120)	125 (78 to 165)	68 (51 to 84)	70 (51 to 93)	3 (-4 to 10)
Uganda	8 (6 to 10)	30 (25 to 38)	270 (188 to 310)	19 (15 to 24)	34 (29 to 44)	83 (52 to 125)	61 (45 to 77)	71 (51 to 101)	16 (10 to 24)
Ukraine	78 (64 to 96)	88 (75 to 114)	13 (-11 to 51)	180 (148 to 221)	267 (225 to 342)	48 (43 to 105)	93 (72 to 124)	88 (62 to 126)	-6 (-11 to 0)
United Arab Emirates	5 (4 to 6)	20 (14 to 26)	304 (259 to 465)	50 (37 to 61)	230 (159 to 298)	358 (223 to 537)	140 (102 to 190)	194 (131 to 289)	38 (27 to 50)
United Kingdom	199 (167 to 241)	307 (265 to 378)	54 (36 to 75)	296 (250 to 359)	416 (360 to 514)	41 (20 to 64)	143 (110 to 177)	152 (115 to 204)	7 (-1 to 15)
United Republic of Tanzania	14 (12 to 17)	48 (41 to 58)	237 (208 to 299)	24 (20 to 29)	40 (35 to 49)	66 (39 to 97)	59 (48 to 72)	72 (55 to 92)	23 (18 to 27)
United States of America	690 (617 to 790)	893 (853 to 1091)	29 (27 to 61)	210 (189 to 242)	249 (238 to 304)	26 (21 to 52)	113 (93 to 133)	136 (110 to 174)	21 (16 to 27)
United States Virgin Islands	0.2 (0.2 to 0.2)	0.2 (0.2 to 0.3)	10 (0 to 37)	199 (161 to 240)	251 (212 to 330)	18 (6 to 72)	104 (81 to 134)	129 (89 to 176)	24 (18 to 30)
Uruguay	7 (6 to 9)	11 (10 to 14)	62 (36 to 88)	203 (174 to 258)	318 (283 to 401)	57 (29 to 92)	121 (92 to 148)	167 (125 to 221)	38 (34 to 43)
Uzbekistan	17 (13 to 20)	50 (42 to 62)	193 (191 to 314)	51 (39 to 59)	118 (100 to 146)	132 (97 to 216)	91 (69 to 114)	100 (73 to 134)	9 (5 to 13)
Vanuatu	0.1 (0.1 to 0.2)	0.3 (0.2 to 0.4)	127 (92 to 205)	45 (39 to 60)	62 (49 to 82)	37 (14 to 70)	95 (69 to 120)	99 (66 to 138)	5 (-2 to 12)

Venezuela (Bolivarian Republic of)	28 (22 to 32)	73 (60 to 88)	159 (117 to 238)	89 (73 to 107)	194 (161 to 236)	119 (83 to 182)	89 (73 to 118)	121 (91 to 162)	36 (27 to 45)
Viet Nam	94 (75 to 118)	263 (225 to 339)	178 (144 to 257)	96 (77 to 121)	249 (212 to 321)	159 (143 to 221)	104 (79 to 136)	146 (104 to 202)	41 (34 to 48)
Yemen	9 (7 to 11)	33 (27 to 42)	260 (226 to 373)	28 (23 to 35)	65 (52 to 81)	129 (99 to 224)	75 (57 to 96)	111 (80 to 154)	49 (40 to 59)
Zambia	4 (3 to 5)	14 (11 to 18)	268 (174 to 427)	20 (16 to 26)	39 (32 to 50)	97 (44 to 139)	63 (45 to 78)	69 (48 to 96)	10 (4 to 15)
Zimbabwe	4 (3 to 5)	10 (8 to 12)	141 (100 to 239)	27 (21 to 33)	38 (31 to 47)	43 (12 to 81)	67 (51 to 91)	70 (48 to 96)	4 (-2 to 10)

Table S5. Average annual percent changes (AAPC) in counts, all-age prevalence and age-standardized prevalence rates of PD from 1990 to 2021, as well as from 2021 to 2050 by 195 countries and territories.

Location	AAPC (number of cases)		AAPC (all-age prevalence)		AAPC (age-standardized prevalence)	
	1990-2021	2021-2050	1990-2021	2021-2050	1990-2021	2021-2050
Afghanistan	2.16 (1.85 to 2.46)	4.90 (4.85 to 4.95)	-1.63 (-2.15 to -1.10)	1.99 (1.94 to 2.04)	0.77 (0.55 to 0.99)	0.89 (0.86 to 0.91)
Albania	3.42 (3.36 to 3.49)	1.64 (1.61 to 1.68)	3.95 (3.74 to 4.16)	1.74 (1.72 to 1.76)	0.29 (0.18 to 0.40)	0.21 (0.20 to 0.23)
Algeria	4.93 (4.87 to 4.99)	4.42 (4.40 to 4.43)	3.09 (2.99 to 3.18)	3.20 (3.17 to 3.23)	0.89 (0.84 to 0.94)	0.86 (0.84 to 0.89)
American Samoa	2.88 (2.73 to 3.03)	2.95 (2.93 to 2.97)	2.18 (2.06 to 2.31)	1.78 (1.76 to 1.79)	0.37 (0.20 to 0.54)	0.09 (0.06 to 0.12)
Andorra	4.48 (4.10 to 4.86)	3.02 (2.98 to 3.07)	3.09 (2.77 to 3.41)	3.53 (3.50 to 3.56)	0.90 (0.71 to 1.08)	0.86 (0.85 to 0.88)
Angola	4.44 (4.36 to 4.52)	4.93 (4.92 to 4.94)	0.66 (0.60 to 0.73)	2.57 (2.56 to 2.58)	0.61 (0.50 to 0.71)	0.67 (0.66 to 0.69)
Antigua and Barbuda	3.26 (3.21 to 3.30)	3.23 (3.20 to 3.25)	1.86 (1.72 to 1.99)	3.17 (3.15 to 3.19)	0.88 (0.80 to 0.97)	1.03 (1.02 to 1.04)
Argentina	2.30 (2.19 to 2.40)	2.31 (2.30 to 2.31)	1.27 (0.97 to 1.57)	1.75 (1.74 to 1.75)	0.36 (0.23 to 0.48)	0.18 (0.16 to 0.19)
Armenia	2.20 (2.07 to 2.32)	1.85 (1.82 to 1.88)	2.54 (2.37 to 2.72)	2.12 (2.08 to 2.16)	0.18 (0.06 to 0.31)	0.13 (0.10 to 0.16)

Australia	3.77 (3.67 to 3.87)	2.13 (2.11 to 2.15)	2.42 (2.33 to 2.52)	1.24 (1.23 to 1.26)	0.99 (0.86 to 1.13)	1.08 (1.05 to 1.11)
Austria	2.60 (2.53 to 2.66)	1.90 (1.89 to 1.92)	2.16 (2.11 to 2.21)	1.95 (1.94 to 1.97)	1.02 (0.84 to 1.20)	0.96 (0.95 to 0.98)
Azerbaijan	2.62 (2.40 to 2.85)	3.75 (3.69 to 3.82)	1.36 (1.18 to 1.54)	3.48 (3.42 to 3.53)	0.44 (0.37 to 0.51)	0.40 (0.38 to 0.41)
Bahamas	3.98 (3.92 to 4.04)	3.06 (3.04 to 3.08)	2.56 (2.48 to 2.65)	2.83 (2.81 to 2.85)	0.52 (0.29 to 0.76)	0.56 (0.55 to 0.58)
Bahrain	7.78 (7.71 to 7.84)	7.26 (7.23 to 7.28)	3.80 (3.64 to 3.95)	6.07 (6.04 to 6.09)	1.30 (1.13 to 1.47)	1.34 (1.30 to 1.38)
Bangladesh	4.55 (4.34 to 4.76)	3.52 (3.52 to 3.53)	3.18 (2.99 to 3.38)	3.35 (3.34 to 3.35)	0.96 (0.87 to 1.06)	0.79 (0.78 to 0.79)
Barbados	2.62 (2.49 to 2.75)	2.00 (1.97 to 2.03)	2.11 (1.95 to 2.28)	2.20 (2.18 to 2.21)	0.79 (0.61 to 0.96)	0.71 (0.69 to 0.72)
Belarus	1.03 (0.90 to 1.16)	1.10 (1.07 to 1.13)	1.38 (1.26 to 1.50)	1.63 (1.60 to 1.66)	0.08 (-0.11 to 0.27)	0.11 (0.10 to 0.12)
Belgium	2.60 (2.48 to 2.73)	1.77 (1.75 to 1.80)	2.12 (1.99 to 2.25)	1.34 (1.32 to 1.37)	1.04 (0.96 to 1.12)	1.06 (1.05 to 1.07)
Belize	4.52 (4.48 to 4.56)	4.32 (4.30 to 4.33)	1.73 (1.69 to 1.78)	3.20 (3.19 to 3.21)	0.68 (0.59 to 0.77)	0.68 (0.67 to 0.69)
Benin	3.40 (3.31 to 3.49)	4.91 (4.89 to 4.93)	0.15 (0.04 to 0.26)	2.67 (2.64 to 2.69)	0.63 (0.43 to 0.83)	0.37 (0.35 to 0.39)
Bermuda	3.35 (3.32 to 3.37)	1.92 (1.90 to 1.95)	2.96 (2.92 to 3.00)	2.34 (2.31 to 2.38)	0.47 (0.33 to 0.60)	0.39 (0.37 to 0.40)
Bhutan	5.07 (4.82 to 5.33)	4.49 (4.48 to 4.50)	3.09 (2.82 to 3.37)	3.89 (3.87 to 3.91)	1.30 (1.05 to 1.56)	1.48 (1.47 to 1.49)

Bolivia (Plurinational State of)	5.30 (5.22 to 5.39)	3.19 (3.19 to 3.20)	3.05 (3.00 to 3.09)	1.74 (1.74 to 1.75)	1.72 (1.64 to 1.80)	1.79 (1.78 to 1.79)
Bosnia and Herzegovina	1.91 (1.81 to 2.02)	1.08 (1.04 to 1.11)	2.91 (2.52 to 3.30)	1.78 (1.76 to 1.81)	0.14 (0.00 to 0.28)	0.02 (0.01 to 0.03)
Botswana	4.23 (4.00 to 4.46)	4.66 (4.65 to 4.67)	2.09 (1.89 to 2.30)	3.59 (3.58 to 3.60)	0.74 (0.60 to 0.88)	0.90 (0.87 to 0.92)
Brazil	4.50 (4.14 to 4.87)	3.05 (3.04 to 3.06)	3.19 (2.95 to 3.42)	2.80 (2.79 to 2.82)	0.82 (0.65 to 0.99)	0.78 (0.77 to 0.79)
Brunei Darussalam	5.53 (5.18 to 5.88)	4.67 (4.62 to 4.71)	3.57 (3.32 to 3.81)	4.14 (4.10 to 4.19)	0.77 (0.52 to 1.03)	0.78 (0.75 to 0.81)
Bulgaria	0.17 (0.03 to 0.31)	-0.58 (-0.59 to -0.58)	0.94 (0.80 to 1.08)	0.43 (0.43 to 0.44)	-0.96 (-1.10 to -0.80)	-1.10 (-1.13 to -1.07)
Burkina Faso	3.01 (2.87 to 3.16)	4.27 (4.26 to 4.27)	0.01 (-0.16 to 0.19)	1.63 (1.60 to 1.66)	0.48 (0.23 to 0.74)	0.40 (0.39 to 0.42)
Burundi	2.28 (2.17 to 2.38)	4.27 (4.25 to 4.28)	-0.32 (-0.47 to -0.17)	1.54 (1.52 to 1.55)	0.35 (0.22 to 0.48)	0.34 (0.30 to 0.38)
Cabo Verde	3.09 (2.83 to 3.35)	4.48 (4.43 to 4.53)	1.54 (1.27 to 1.80)	3.83 (3.77 to 3.88)	1.07 (0.81 to 1.32)	1.24 (1.22 to 1.25)
Cambodia	4.40 (4.32 to 4.49)	3.91 (3.90 to 3.92)	2.69 (2.59 to 2.79)	3.21 (3.19 to 3.23)	0.90 (0.83 to 0.96)	1.03 (1.01 to 1.04)
Cameroon	4.03 (3.92 to 4.15)	4.54 (4.53 to 4.55)	0.47 (0.27 to 0.66)	3.04 (3.02 to 3.06)	0.64 (0.43 to 0.85)	0.39 (0.38 to 0.41)
Canada	4.32 (4.28 to 4.37)	1.92 (1.90 to 1.95)	3.27 (3.18 to 3.36)	1.40 (1.37 to 1.42)	1.47 (1.39 to 1.55)	1.42 (1.41 to 1.42)
Central African Republic	2.35 (2.31 to 2.38)	2.96 (2.95 to 2.97)	0.54 (0.49 to 0.59)	2.73 (2.72 to 2.74)	0.34 (0.11 to 0.56)	0.33 (0.32 to 0.35)

Chad	2.71 (2.47 to 2.96)	4.54 (4.53 to 4.55)	-0.81 (-1.05 to -0.57)	0.88 (0.85 to 0.91)	0.52 (0.40 to 0.63)	0.59 (0.58 to 0.60)
Chile	4.62 (4.22 to 5.03)	2.95 (2.92 to 2.98)	3.48 (3.22 to 3.75)	2.64 (2.62 to 2.65)	1.04 (0.66 to 1.43)	1.26 (1.22 to 1.30)
China	6.81 (6.73 to 6.88)	2.63 (2.62 to 2.65)	6.13 (6.06 to 6.20)	3.05 (3.03 to 3.06)	3.11 (2.90 to 3.32)	3.07 (3.07 to 3.08)
Colombia	5.60 (5.53 to 5.66)	3.26 (3.25 to 3.27)	3.88 (3.68 to 4.07)	2.72 (2.71 to 2.73)	1.01 (0.88 to 1.14)	1.05 (1.04 to 1.07)
Comoros	2.90 (2.71 to 3.09)	3.73 (3.72 to 3.74)	1.23 (1.02 to 1.45)	2.84 (2.84 to 2.85)	0.53 (0.35 to 0.70)	0.64 (0.59 to 0.68)
Congo	3.57 (3.49 to 3.64)	4.47 (4.45 to 4.49)	1.00 (0.85 to 1.16)	3.61 (3.60 to 3.62)	0.66 (0.52 to 0.79)	0.54 (0.53 to 0.56)
Costa Rica	4.81 (4.72 to 4.91)	3.30 (3.28 to 3.32)	3.22 (3.14 to 3.30)	2.86 (2.84 to 2.88)	0.87 (0.58 to 1.16)	0.98 (0.98 to 0.99)
Côte d'Ivoire	4.19 (4.06 to 4.32)	5.13 (5.12 to 5.14)	1.41 (1.33 to 1.49)	3.11 (3.09 to 3.12)	0.58 (0.35 to 0.80)	0.48 (0.45 to 0.50)
Croatia	1.77 (1.72 to 1.82)	0.83 (0.82 to 0.85)	2.30 (2.23 to 2.37)	1.72 (1.71 to 1.73)	0.28 (0.17 to 0.38)	0.18 (0.16 to 0.20)
Cuba	3.30 (3.13 to 3.46)	2.46 (2.44 to 2.47)	3.17 (3.01 to 3.33)	3.12 (3.11 to 3.13)	1.00 (0.92 to 1.09)	1.21 (1.19 to 1.23)
Cyprus	3.97 (3.84 to 4.10)	2.46 (2.45 to 2.48)	2.29 (2.21 to 2.38)	2.36 (2.36 to 2.36)	0.53 (0.37 to 0.69)	0.44 (0.43 to 0.45)
Czechia	2.26 (2.22 to 2.31)	1.24 (1.22 to 1.26)	2.14 (2.09 to 2.18)	1.57 (1.55 to 1.58)	0.60 (0.36 to 0.85)	0.42 (0.41 to 0.42)
Democratic People's Republic of Korea	4.99 (4.88 to 5.10)	2.02 (2.00 to 2.05)	4.22 (4.09 to 4.36)	2.36 (2.34 to 2.38)	2.12 (1.91 to 2.33)	2.27 (2.25 to 2.30)

Democratic Republic of the Congo	3.40 (3.33 to 3.48)	3.57 (3.48 to 3.65)	0.57 (0.49 to 0.66)	1.31 (1.24 to 1.39)	0.46 (0.38 to 0.53)	0.39 (0.38 to 0.39)
Denmark	3.00 (2.94 to 3.07)	1.39 (1.37 to 1.40)	2.59 (2.53 to 2.65)	1.17 (1.16 to 1.18)	1.75 (1.58 to 1.92)	1.72 (1.71 to 1.74)
Djibouti	5.86 (5.83 to 5.89)	4.71 (4.70 to 4.72)	2.71 (2.57 to 2.86)	3.80 (3.78 to 3.81)	0.66 (0.51 to 0.81)	0.62 (0.61 to 0.63)
Dominica	1.59 (1.43 to 1.75)	1.70 (1.69 to 1.72)	1.74 (1.58 to 1.90)	1.80 (1.77 to 1.82)	0.63 (0.46 to 0.80)	0.60 (0.59 to 0.62)
Dominican Republic	4.46 (4.29 to 4.63)	3.06 (3.05 to 3.07)	3.05 (2.87 to 3.24)	2.69 (2.68 to 2.69)	0.99 (0.84 to 1.14)	0.93 (0.92 to 0.94)
Ecuador	5.88 (5.81 to 5.94)	3.11 (3.10 to 3.12)	3.98 (3.88 to 4.08)	2.37 (2.36 to 2.37)	1.88 (1.76 to 1.99)	1.83 (1.82 to 1.84)
Egypt	3.92 (3.80 to 4.04)	4.39 (4.37 to 4.40)	1.82 (1.68 to 1.96)	3.05 (3.04 to 3.06)	1.34 (1.16 to 1.52)	1.49 (1.48 to 1.51)
El Salvador	3.58 (3.43 to 3.74)	2.48 (2.47 to 2.48)	3.00 (2.86 to 3.14)	2.80 (2.78 to 2.81)	1.00 (0.74 to 1.26)	1.19 (1.18 to 1.20)
Equatorial Guinea	4.65 (4.60 to 4.70)	5.79 (5.78 to 5.80)	0.39 (0.31 to 0.47)	3.85 (3.83 to 3.87)	1.42 (1.27 to 1.56)	1.36 (1.36 to 1.37)
Eritrea	3.66 (3.43 to 3.88)	4.62 (4.61 to 4.63)	1.09 (1.01 to 1.18)	3.42 (3.41 to 3.43)	0.47 (0.37 to 0.58)	0.42 (0.40 to 0.43)
Estonia	0.94 (0.57 to 1.32)	0.74 (0.73 to 0.75)	1.54 (1.18 to 1.91)	1.15 (1.14 to 1.16)	-0.28 (-0.43 to -0.12)	-0.15 (-0.16 to -0.13)
Eswatini	2.98 (2.94 to 3.02)	3.53 (3.52 to 3.54)	1.63 (1.52 to 1.75)	2.42 (2.40 to 2.44)	0.47 (0.34 to 0.60)	0.52 (0.52 to 0.53)
Ethiopia	3.32 (3.27 to 3.36)	5.07 (5.06 to 5.07)	0.60 (0.58 to 0.63)	2.98 (2.96 to 3.00)	0.44 (0.30 to 0.58)	0.50 (0.48 to 0.51)

Fiji	3.05 (2.94 to 3.17)	2.55 (2.54 to 2.56)	2.41 (2.30 to 2.52)	2.01 (2.00 to 2.02)	0.22 (0.10 to 0.35)	0.10 (0.06 to 0.13)
Finland	3.40 (3.31 to 3.48)	1.00 (0.99 to 1.02)	3.03 (2.94 to 3.12)	0.94 (0.92 to 0.95)	1.25 (1.04 to 1.45)	1.62 (1.61 to 1.63)
France	2.97 (2.93 to 3.02)	1.46 (1.44 to 1.48)	2.49 (2.45 to 2.53)	1.27 (1.25 to 1.29)	0.89 (0.76 to 1.02)	1.07 (1.06 to 1.09)
Gabon	2.94 (2.77 to 3.10)	4.00 (3.98 to 4.01)	0.90 (0.76 to 1.03)	2.99 (2.98 to 3.00)	0.60 (0.49 to 0.71)	0.64 (0.63 to 0.66)
Gambia	4.35 (4.31 to 4.40)	4.37 (4.34 to 4.39)	1.45 (1.41 to 1.48)	2.73 (2.68 to 2.78)	0.81 (0.63 to 0.99)	0.87 (0.86 to 0.88)
Georgia	-0.97 (-1.22 to -0.72)	0.43 (0.40 to 0.46)	1.06 (0.94 to 1.19)	0.71 (0.67 to 0.74)	-0.32 (-0.43 to -0.20)	-0.46 (-0.46 to -0.45)
Germany	3.95 (3.83 to 4.07)	1.26 (1.25 to 1.28)	3.79 (3.67 to 3.90)	1.30 (1.28 to 1.31)	2.26 (2.11 to 2.42)	2.01 (1.99 to 2.02)
Ghana	4.14 (4.08 to 4.19)	4.46 (4.45 to 4.47)	1.53 (1.38 to 1.68)	3.02 (3.01 to 3.03)	0.78 (0.38 to 1.19)	0.75 (0.73 to 0.77)
Greece	2.58 (2.42 to 2.73)	1.40 (1.39 to 1.41)	2.60 (2.50 to 2.71)	1.89 (1.88 to 1.90)	0.69 (0.54 to 0.84)	0.67 (0.65 to 0.69)
Greenland	3.76 (3.68 to 3.85)	2.64 (2.58 to 2.70)	3.63 (3.54 to 3.71)	2.54 (2.50 to 2.57)	0.65 (0.39 to 0.91)	0.72 (0.69 to 0.74)
Grenada	4.00 (3.37 to 4.64)	1.70 (1.68 to 1.72)	3.01 (2.37 to 3.66)	1.73 (1.71 to 1.76)	0.92 (0.78 to 1.06)	0.90 (0.89 to 0.92)
Guam	3.69 (3.61 to 3.77)	2.39 (2.37 to 2.41)	2.86 (2.77 to 2.96)	1.74 (1.73 to 1.76)	-0.10 (-0.28 to 0.08)	0.05 (0.05 to 0.06)
Guatemala	5.17 (5.08 to 5.26)	4.16 (4.15 to 4.16)	2.38 (2.34 to 2.42)	3.07 (3.06 to 3.08)	0.74 (0.60 to 0.88)	0.81 (0.79 to 0.82)

Guinea	2.20 (2.12 to 2.28)	3.73 (3.69 to 3.76)	-0.26 (-0.41 to -0.10)	1.72 (1.67 to 1.77)	0.69 (0.56 to 0.81)	0.58 (0.57 to 0.59)
Guinea-Bissau	2.32 (2.26 to 2.39)	4.58 (4.56 to 4.59)	-0.05 (-0.12 to 0.01)	2.81 (2.78 to 2.85)	0.33 (0.21 to 0.46)	0.46 (0.44 to 0.48)
Guyana	2.57 (2.51 to 2.62)	2.65 (2.64 to 2.66)	2.58 (2.52 to 2.65)	2.34 (2.33 to 2.35)	0.61 (0.46 to 0.75)	0.55 (0.53 to 0.56)
Haiti	3.26 (3.07 to 3.45)	3.45 (3.44 to 3.46)	0.99 (0.94 to 1.05)	2.57 (2.57 to 2.58)	0.53 (0.28 to 0.78)	0.46 (0.44 to 0.47)
Honduras	5.40 (5.33 to 5.48)	4.43 (4.43 to 4.44)	2.74 (2.68 to 2.80)	3.12 (3.11 to 3.13)	1.23 (0.99 to 1.48)	1.52 (1.51 to 1.54)
Hungary	1.52 (1.43 to 1.61)	1.02 (1.01 to 1.04)	1.77 (1.68 to 1.85)	1.60 (1.58 to 1.61)	0.48 (0.32 to 0.64)	0.54 (0.53 to 0.56)
Iceland	3.29 (3.20 to 3.39)	2.37 (2.34 to 2.40)	2.22 (2.04 to 2.40)	1.90 (1.87 to 1.93)	0.83 (0.61 to 1.05)	1.12 (1.10 to 1.13)
India	4.65 (4.57 to 4.73)	3.60 (3.60 to 3.61)	2.86 (2.78 to 2.94)	3.20 (3.19 to 3.20)	1.12 (1.04 to 1.19)	1.29 (1.27 to 1.30)
Indonesia	3.94 (3.84 to 4.04)	3.89 (3.87 to 3.92)	2.70 (2.60 to 2.81)	3.48 (3.46 to 3.50)	0.91 (0.85 to 0.98)	0.92 (0.90 to 0.93)
Iran (Islamic Republic of)	5.48 (5.39 to 5.58)	4.50 (4.48 to 4.52)	4.06 (3.96 to 4.16)	4.10 (4.09 to 4.11)	1.15 (1.02 to 1.29)	1.25 (1.22 to 1.28)
Iraq	5.67 (5.56 to 5.79)	5.48 (5.47 to 5.48)	2.23 (2.14 to 2.33)	3.55 (3.55 to 3.56)	1.50 (1.29 to 1.70)	1.61 (1.58 to 1.65)
Ireland	3.53 (3.36 to 3.69)	2.71 (2.70 to 2.73)	2.41 (2.18 to 2.65)	2.24 (2.23 to 2.25)	1.14 (0.99 to 1.29)	1.18 (1.17 to 1.18)
Israel	3.81 (3.72 to 3.91)	2.68 (2.65 to 2.71)	1.66 (1.60 to 1.72)	1.25 (1.24 to 1.27)	0.42 (0.24 to 0.60)	0.32 (0.32 to 0.33)

Italy	0.73 (0.39 to 1.07)	-0.24 (-0.24 to -0.23)	0.49 (0.19 to 0.79)	0.26 (0.25 to 0.26)	-1.18 (-1.50 to -0.86)	-1.67 (-1.67 to -1.66)
Jamaica	2.45 (2.30 to 2.60)	2.54 (2.52 to 2.56)	1.88 (1.83 to 1.93)	2.99 (2.98 to 3.00)	0.66 (0.46 to 0.86)	0.73 (0.72 to 0.75)
Japan	1.84 (1.59 to 2.09)	0.37 (0.35 to 0.38)	1.84 (1.58 to 2.10)	1.09 (1.08 to 1.10)	-0.42 (-0.77 to -0.08)	-0.18 (-0.20 to -0.16)
Jordan	6.42 (6.28 to 6.57)	5.53 (5.52 to 5.55)	2.62 (2.49 to 2.76)	3.95 (3.94 to 3.96)	0.59 (0.48 to 0.70)	1.03 (1.01 to 1.06)
Kazakhstan	1.88 (1.80 to 1.96)	3.55 (3.52 to 3.58)	1.43 (1.36 to 1.50)	2.65 (2.63 to 2.67)	0.75 (0.51 to 0.98)	0.71 (0.69 to 0.72)
Kenya	3.94 (3.89 to 3.98)	4.37 (4.37 to 4.38)	1.18 (1.15 to 1.20)	2.95 (2.94 to 2.96)	0.48 (0.37 to 0.59)	0.45 (0.43 to 0.47)
Kiribati	2.55 (2.28 to 2.82)	3.03 (3.02 to 3.05)	0.71 (0.56 to 0.85)	1.28 (1.27 to 1.28)	0.36 (0.19 to 0.52)	0.30 (0.28 to 0.33)
Kuwait	6.52 (6.38 to 6.67)	7.05 (7.02 to 7.07)	3.29 (3.12 to 3.45)	6.25 (6.22 to 6.27)	0.82 (0.60 to 1.04)	0.86 (0.85 to 0.87)
Kyrgyzstan	1.18 (1.06 to 1.29)	3.68 (3.65 to 3.71)	-0.19 (-0.30 to -0.07)	2.51 (2.48 to 2.55)	0.05 (-0.05 to 0.16)	-0.04 (-0.06 to -0.02)
Lao People's Democratic Republic	3.33 (3.27 to 3.39)	4.40 (4.38 to 4.41)	1.39 (1.35 to 1.44)	3.61 (3.60 to 3.62)	0.60 (0.46 to 0.73)	0.67 (0.66 to 0.68)
Latvia	0.63 (0.39 to 0.88)	0.05 (0.04 to 0.07)	1.78 (1.51 to 2.05)	1.45 (1.44 to 1.45)	0.07 (-0.22 to 0.36)	-0.28 (-0.29 to -0.26)
Lebanon	4.94 (4.84 to 5.04)	4.21 (4.19 to 4.23)	1.27 (0.98 to 1.57)	3.34 (3.32 to 3.37)	1.07 (0.96 to 1.17)	1.12 (1.09 to 1.14)
Lesotho	1.35 (1.25 to 1.44)	2.46 (2.44 to 2.48)	0.98 (0.93 to 1.03)	1.72 (1.69 to 1.75)	0.67 (0.58 to 0.76)	0.76 (0.76 to 0.77)

Liberia	2.37 (2.27 to 2.48)	4.08 (4.04 to 4.11)	-0.80 (-1.03 to -0.57)	2.50 (2.46 to 2.54)	0.42 (0.15 to 0.70)	0.40 (0.38 to 0.41)
Libya	4.37 (4.18 to 4.55)	2.32 (2.19 to 2.45)	2.45 (2.13 to 2.77)	1.54 (1.12 to 1.97)	1.27 (1.17 to 1.38)	1.34 (1.32 to 1.35)
Lithuania	1.18 (1.10 to 1.26)	0.30 (0.28 to 0.32)	2.05 (1.68 to 2.42)	1.02 (1.00 to 1.04)	-0.06 (-0.36 to 0.24)	-0.14 (-0.14 to -0.12)
Luxembourg	3.07 (3.00 to 3.15)	2.76 (2.74 to 2.78)	1.48 (1.43 to 1.53)	2.06 (2.04 to 2.09)	0.88 (0.75 to 1.01)	1.21 (1.20 to 1.23)
Madagascar	3.02 (2.99 to 3.04)	4.40 (4.39 to 4.41)	0.04 (-0.04 to 0.13)	1.75 (1.74 to 1.76)	0.37 (0.19 to 0.56)	0.49 (0.47 to 0.51)
Malawi	3.16 (2.97 to 3.35)	4.25 (4.24 to 4.27)	0.93 (0.64 to 1.22)	2.29 (2.26 to 2.33)	0.46 (0.20 to 0.71)	0.33 (0.30 to 0.37)
Malaysia	4.76 (4.66 to 4.85)	3.84 (3.83 to 3.85)	2.71 (2.65 to 2.76)	2.92 (2.91 to 2.92)	0.92 (0.74 to 1.10)	0.98 (0.97 to 0.99)
Maldives	5.65 (5.38 to 5.92)	5.86 (5.84 to 5.88)	2.89 (2.56 to 3.22)	4.80 (4.77 to 4.83)	0.70 (0.55 to 0.85)	0.73 (0.70 to 0.75)
Mali	3.13 (3.10 to 3.15)	4.38 (4.37 to 4.39)	-0.09 (-0.22 to 0.04)	1.43 (1.41 to 1.44)	0.52 (0.31 to 0.73)	0.38 (0.36 to 0.39)
Malta	4.04 (3.96 to 4.13)	1.19 (1.17 to 1.21)	3.47 (3.41 to 3.53)	1.40 (1.38 to 1.41)	1.15 (1.02 to 1.28)	0.99 (0.98 to 1.01)
Marshall Islands	2.72 (2.56 to 2.88)	3.68 (3.67 to 3.69)	1.76 (1.71 to 1.80)	2.70 (2.69 to 2.71)	0.48 (0.31 to 0.65)	0.48 (0.46 to 0.49)
Mauritania	3.19 (3.06 to 3.32)	4.56 (4.55 to 4.56)	0.69 (0.56 to 0.82)	2.58 (2.56 to 2.60)	0.74 (0.61 to 0.87)	0.49 (0.45 to 0.53)
Mauritius	3.93 (3.89 to 3.97)	2.54 (2.52 to 2.56)	3.39 (3.34 to 3.43)	2.77 (2.75 to 2.78)	0.61 (0.53 to 0.69)	0.65 (0.63 to 0.66)

Mexico	4.98 (4.92 to 5.03)	3.62 (3.61 to 3.63)	3.43 (3.39 to 3.47)	2.81 (2.80 to 2.81)	1.06 (0.75 to 1.37)	1.15 (1.14 to 1.17)
Micronesia (Federated States of)	2.06 (1.82 to 2.31)	3.35 (3.33 to 3.37)	1.82 (1.68 to 1.97)	2.24 (2.22 to 2.26)	0.48 (0.34 to 0.62)	0.45 (0.44 to 0.47)
Mongolia	2.43 (2.35 to 2.51)	4.29 (4.26 to 4.32)	0.90 (0.74 to 1.05)	3.32 (3.28 to 3.37)	0.07 (-0.18 to 0.32)	0.07 (0.05 to 0.09)
Montenegro	2.06 (1.94 to 2.17)	1.24 (1.22 to 1.26)	2.07 (1.96 to 2.18)	1.45 (1.42 to 1.48)	0.09 (-0.08 to 0.26)	0.13 (0.12 to 0.13)
Morocco	4.82 (4.66 to 4.97)	3.49 (3.46 to 3.52)	3.50 (3.29 to 3.72)	2.98 (2.97 to 2.99)	1.58 (1.49 to 1.67)	1.64 (1.62 to 1.66)
Mozambique	2.82 (2.77 to 2.87)	4.41 (4.41 to 4.42)	-0.27 (-0.50 to -0.05)	2.84 (2.82 to 2.87)	0.32 (0.00 to 0.66)	0.46 (0.44 to 0.48)
Myanmar	3.57 (3.52 to 3.62)	3.46 (3.42 to 3.49)	2.58 (2.49 to 2.67)	2.92 (2.90 to 2.94)	1.07 (1.00 to 1.14)	0.94 (0.92 to 0.96)
Namibia	3.29 (3.17 to 3.40)	4.16 (4.15 to 4.17)	1.33 (1.26 to 1.39)	2.73 (2.72 to 2.74)	0.67 (0.50 to 0.84)	0.82 (0.81 to 0.82)
Nepal	4.80 (4.77 to 4.83)	3.28 (3.27 to 3.29)	3.15 (3.10 to 3.20)	2.94 (2.92 to 2.95)	1.54 (1.44 to 1.64)	1.67 (1.63 to 1.71)
Netherlands	2.12 (1.99 to 2.24)	1.31 (1.29 to 1.33)	1.64 (1.53 to 1.75)	1.39 (1.37 to 1.40)	0.17 (0.07 to 0.27)	-0.20 (-0.21 to -0.20)
New Zealand	3.05 (3.01 to 3.08)	1.89 (1.87 to 1.91)	2.03 (2.01 to 2.05)	1.27 (1.25 to 1.28)	0.39 (0.21 to 0.56)	0.63 (0.61 to 0.64)
Nicaragua	5.42 (5.36 to 5.48)	3.91 (3.90 to 3.91)	3.51 (3.46 to 3.55)	3.32 (3.31 to 3.32)	1.01 (0.73 to 1.29)	0.92 (0.91 to 0.93)
Niger	4.04 (3.95 to 4.14)	4.52 (4.51 to 4.54)	0.29 (0.18 to 0.41)	0.60 (0.59 to 0.61)	0.40 (0.22 to 0.58)	0.40 (0.38 to 0.42)

Nigeria	3.24 (3.02 to 3.46)	5.41 (5.38 to 5.44)	0.10 (-0.07 to 0.27)	2.70 (2.69 to 2.72)	0.86 (0.69 to 1.04)	0.75 (0.73 to 0.77)
North Macedonia	3.10 (3.00 to 3.20)	1.95 (1.94 to 1.97)	2.80 (2.57 to 3.02)	2.25 (2.23 to 2.26)	0.27 (0.17 to 0.38)	0.46 (0.43 to 0.48)
Northern Mariana Islands	5.10 (4.83 to 5.36)	3.17 (3.08 to 3.26)	4.95 (4.32 to 5.58)	2.93 (2.84 to 3.02)	0.35 (0.08 to 0.61)	-0.04 (-0.08 to 0.02)
Norway	5.66 (5.56 to 5.76)	2.08 (2.07 to 2.09)	4.80 (4.71 to 4.89)	1.36 (1.35 to 1.37)	4.32 (4.02 to 4.62)	4.82 (4.81 to 4.84)
Oman	6.27 (5.87 to 6.66)	7.60 (7.58 to 7.62)	3.02 (2.63 to 3.41)	5.90 (5.87 to 5.92)	1.81 (1.69 to 1.94)	1.66 (1.64 to 1.68)
Pakistan	3.09 (2.99 to 3.19)	4.08 (4.07 to 4.09)	0.70 (0.65 to 0.74)	3.03 (3.03 to 3.04)	0.84 (0.75 to 0.94)	0.93 (0.92 to 0.95)
Palestine	4.86 (4.78 to 4.94)	5.03 (5.00 to 5.06)	1.64 (1.52 to 1.76)	3.37 (3.36 to 3.39)	1.02 (0.82 to 1.22)	1.20 (1.17 to 1.22)
Panama	4.94 (4.85 to 5.04)	3.26 (3.25 to 3.27)	3.09 (3.00 to 3.17)	2.13 (2.12 to 2.14)	0.98 (0.64 to 1.32)	1.09 (1.07 to 1.11)
Papua New Guinea	3.23 (3.17 to 3.30)	4.17 (4.16 to 4.18)	0.23 (0.11 to 0.36)	2.23 (2.22 to 2.24)	0.33 (0.11 to 0.54)	0.27 (0.25 to 0.30)
Paraguay	4.10 (3.96 to 4.23)	3.39 (3.39 to 3.40)	2.12 (2.05 to 2.18)	2.57 (2.57 to 2.58)	0.72 (0.48 to 0.97)	0.81 (0.79 to 0.82)
Peru	5.47 (5.39 to 5.55)	3.34 (3.33 to 3.35)	3.78 (3.70 to 3.85)	2.19 (2.18 to 2.19)	1.79 (1.54 to 2.04)	1.83 (1.81 to 1.85)
Philippines	3.65 (3.61 to 3.69)	3.40 (3.39 to 3.42)	1.81 (1.74 to 1.87)	2.25 (2.24 to 2.26)	0.42 (0.32 to 0.52)	0.35 (0.34 to 0.36)
Poland	2.37 (2.33 to 2.41)	1.44 (1.43 to 1.46)	2.36 (2.33 to 2.39)	2.07 (2.04 to 2.10)	0.35 (0.22 to 0.49)	0.44 (0.43 to 0.46)

Portugal	3.36 (3.29 to 3.43)	1.69 (1.67 to 1.71)	3.23 (3.12 to 3.33)	2.36 (2.35 to 2.36)	1.21 (1.07 to 1.34)	1.13 (1.12 to 1.14)
Puerto Rico	3.18 (3.07 to 3.29)	1.47 (1.45 to 1.49)	3.16 (3.07 to 3.25)	2.26 (2.25 to 2.27)	0.65 (0.53 to 0.76)	0.59 (0.55 to 0.63)
Qatar	9.64 (9.44 to 9.83)	9.94 (9.90 to 9.98)	3.07 (2.72 to 3.42)	9.23 (9.18 to 9.27)	1.42 (1.16 to 1.68)	1.66 (1.65 to 1.67)
Republic of Korea	6.25 (6.16 to 6.35)	3.28 (3.25 to 3.32)	5.60 (5.50 to 5.70)	3.51 (3.47 to 3.56)	1.70 (1.53 to 1.86)	1.76 (1.75 to 1.77)
Republic of Moldova	0.77 (0.70 to 0.84)	1.60 (1.58 to 1.63)	1.35 (1.22 to 1.47)	2.33 (2.31 to 2.35)	-0.52 (-0.75 to -0.29)	-0.67 (-0.69 to -0.64)
Romania	1.85 (1.76 to 1.94)	1.16 (1.14 to 1.18)	2.52 (2.44 to 2.61)	1.99 (1.97 to 2.00)	0.54 (0.41 to 0.66)	0.42 (0.42 to 0.43)
Russian Federation	1.22 (1.11 to 1.33)	1.24 (1.20 to 1.27)	1.33 (1.23 to 1.44)	1.54 (1.50 to 1.58)	-0.01 (-0.29 to 0.27)	0.08 (0.07 to 0.10)
Rwanda	2.79 (2.50 to 3.08)	4.71 (4.70 to 4.72)	0.85 (0.42 to 1.27)	2.54 (2.52 to 2.55)	0.28 (0.08 to 0.47)	0.41 (0.37 to 0.44)
Saint Lucia	3.87 (3.83 to 3.91)	2.80 (2.78 to 2.81)	2.90 (2.85 to 2.95)	2.70 (2.69 to 2.71)	0.58 (0.43 to 0.73)	0.47 (0.45 to 0.50)
Saint Vincent and the Grenadines	3.10 (2.98 to 3.23)	1.88 (1.86 to 1.90)	2.95 (2.84 to 3.06)	2.36 (2.34 to 2.38)	0.74 (0.53 to 0.96)	0.70 (0.67 to 0.73)
Samoa	2.15 (1.97 to 2.34)	2.90 (2.87 to 2.93)	1.29 (1.14 to 1.45)	0.96 (0.92 to 1.00)	0.48 (0.26 to 0.71)	0.42 (0.39 to 0.44)
Sao Tome and Principe	2.56 (2.40 to 2.73)	4.52 (4.51 to 4.54)	0.66 (0.55 to 0.77)	3.59 (3.57 to 3.60)	0.97 (0.74 to 1.19)	0.95 (0.93 to 0.96)
Saudi Arabia	5.44 (5.35 to 5.52)	6.92 (6.90 to 6.93)	2.62 (2.55 to 2.69)	6.19 (6.17 to 6.21)	1.51 (1.39 to 1.62)	1.72 (1.67 to 1.76)

Senegal	3.66 (3.56 to 3.77)	4.30 (4.29 to 4.30)	1.09 (1.01 to 1.18)	2.34 (2.32 to 2.35)	0.79 (0.57 to 1.00)	0.64 (0.62 to 0.65)
Serbia	1.88 (1.77 to 2.00)	0.98 (0.95 to 1.01)	2.14 (1.87 to 2.40)	1.62 (1.60 to 1.65)	0.32 (0.26 to 0.38)	0.45 (0.44 to 0.46)
Seychelles	2.84 (2.74 to 2.95)	3.41 (3.36 to 3.46)	1.66 (1.55 to 1.76)	3.23 (3.19 to 3.27)	0.73 (0.61 to 0.85)	0.73 (0.72 to 0.74)
Sierra Leone	2.37 (2.31 to 2.44)	4.20 (4.19 to 4.22)	-0.44 (-0.59 to -0.30)	2.64 (2.61 to 2.68)	0.49 (0.22 to 0.75)	0.46 (0.44 to 0.49)
Singapore	5.47 (5.35 to 5.59)	4.28 (4.25 to 4.31)	3.16 (2.81 to 3.51)	3.30 (3.27 to 3.34)	0.75 (0.60 to 0.90)	0.93 (0.92 to 0.94)
Slovakia	1.83 (1.75 to 1.90)	1.58 (1.57 to 1.60)	1.73 (1.67 to 1.80)	2.09 (2.08 to 2.11)	0.23 (0.07 to 0.38)	0.16 (0.14 to 0.17)
Slovenia	2.33 (2.28 to 2.38)	1.31 (1.29 to 1.33)	2.17 (2.11 to 2.22)	1.75 (1.71 to 1.78)	0.11 (-0.09 to 0.31)	0.15 (0.13 to 0.17)
Solomon Islands	3.80 (3.41 to 4.19)	3.77 (3.75 to 3.78)	1.41 (1.00 to 1.82)	2.29 (2.28 to 2.30)	0.37 (0.17 to 0.57)	0.19 (0.17 to 0.21)
Somalia	3.59 (3.53 to 3.64)	3.48 (3.46 to 3.51)	0.41 (0.31 to 0.51)	0.96 (0.94 to 0.98)	0.18 (0.01 to 0.35)	0.18 (0.17 to 0.19)
South Africa	3.45 (3.41 to 3.50)	3.40 (3.39 to 3.41)	1.93 (1.87 to 1.98)	2.52 (2.50 to 2.54)	0.59 (0.42 to 0.75)	0.70 (0.68 to 0.71)
South Sudan	1.79 (1.75 to 1.83)	4.71 (4.70 to 4.72)	-0.42 (-0.67 to -0.17)	1.53 (1.52 to 1.54)	0.22 (0.03 to 0.40)	0.24 (0.21 to 0.26)
Spain	2.88 (2.59 to 3.16)	2.19 (2.16 to 2.21)	2.25 (2.14 to 2.35)	2.57 (2.55 to 2.58)	0.65 (0.48 to 0.82)	0.52 (0.49 to 0.55)
Sri Lanka	4.29 (4.16 to 4.41)	2.76 (2.73 to 2.79)	3.52 (3.36 to 3.68)	2.92 (2.91 to 2.93)	1.01 (0.85 to 1.17)	0.93 (0.91 to 0.94)

Sudan	3.73 (3.66 to 3.81)	5.03 (5.02 to 5.04)	1.03 (0.87 to 1.19)	3.36 (3.33 to 3.39)	1.10 (0.96 to 1.24)	1.32 (1.28 to 1.35)
Suriname	3.84 (3.73 to 3.94)	2.53 (2.51 to 2.54)	2.39 (2.28 to 2.49)	2.11 (2.10 to 2.13)	0.82 (0.59 to 1.04)	0.95 (0.94 to 0.96)
Sweden	2.82 (2.68 to 2.96)	2.06 (2.05 to 2.07)	2.22 (2.11 to 2.33)	1.58 (1.57 to 1.59)	1.45 (1.22 to 1.67)	1.54 (1.51 to 1.56)
Switzerland	2.77 (2.68 to 2.85)	2.09 (2.07 to 2.11)	1.91 (1.83 to 1.99)	1.75 (1.74 to 1.76)	1.01 (0.80 to 1.22)	1.02 (1.00 to 1.03)
Syrian Arab Republic	4.91 (4.64 to 5.17)	4.76 (4.74 to 4.77)	3.59 (3.17 to 4.02)	4.41 (4.39 to 4.42)	1.37 (1.18 to 1.56)	1.47 (1.46 to 1.48)
Taiwan (Province of China)	7.38 (7.14 to 7.61)	2.59 (2.55 to 2.64)	6.83 (6.61 to 7.05)	3.04 (3.01 to 3.07)	3.43 (3.15 to 3.70)	4.31 (4.30 to 4.31)
Tajikistan	2.54 (2.18 to 2.91)	2.96 (2.68 to 3.24)	0.39 (0.06 to 0.72)	1.31 (1.03 to 1.58)	0.70 (0.48 to 0.91)	0.52 (0.51 to 0.53)
Thailand	4.84 (4.64 to 5.04)	3.36 (3.34 to 3.38)	4.05 (3.92 to 4.18)	3.64 (3.62 to 3.65)	0.56 (0.39 to 0.73)	0.59 (0.59 to 0.60)
Timor-Leste	5.21 (4.99 to 5.43)	3.46 (3.45 to 3.48)	3.23 (3.03 to 3.42)	1.79 (1.77 to 1.82)	0.76 (0.60 to 0.92)	0.83 (0.82 to 0.84)
Togo	4.24 (4.13 to 4.36)	4.61 (4.60 to 4.62)	1.55 (1.43 to 1.67)	3.30 (3.29 to 3.31)	0.55 (0.42 to 0.68)	0.57 (0.54 to 0.59)
Tonga	2.03 (1.90 to 2.17)	3.01 (3.00 to 3.02)	1.58 (1.54 to 1.61)	1.38 (1.38 to 1.39)	0.54 (0.42 to 0.66)	0.39 (0.38 to 0.41)
Trinidad and Tobago	3.53 (3.42 to 3.64)	2.37 (2.35 to 2.38)	2.97 (2.89 to 3.06)	2.44 (2.43 to 2.45)	0.53 (0.36 to 0.69)	0.63 (0.60 to 0.66)
Tunisia	4.70 (4.62 to 4.78)	3.72 (3.70 to 3.74)	3.49 (3.42 to 3.56)	3.24 (3.21 to 3.27)	1.12 (0.99 to 1.25)	1.32 (1.30 to 1.33)

Turkey	5.19 (5.11 to 5.27)	4.20 (4.17 to 4.22)	3.96 (3.88 to 4.05)	3.32 (3.30 to 3.34)	1.41 (1.25 to 1.57)	1.56 (1.54 to 1.58)
Turkmenistan	2.69 (2.57 to 2.81)	3.81 (3.78 to 3.85)	1.50 (1.41 to 1.59)	2.80 (2.76 to 2.83)	0.16 (0.07 to 0.25)	0.09 (0.07 to 0.11)
Uganda	3.27 (3.15 to 3.40)	4.91 (4.90 to 4.92)	0.11 (0.06 to 0.16)	2.42 (2.40 to 2.45)	0.58 (0.47 to 0.69)	0.52 (0.50 to 0.54)
Ukraine	0.33 (-0.14 to 0.80)	0.62 (0.61 to 0.64)	0.95 (0.66 to 1.25)	1.56 (1.53 to 1.59)	-0.24 (-0.55 to 0.01)	-0.21 (-0.23 to -0.20)
United Arab Emirates	9.54 (9.24 to 9.84)	4.97 (4.60 to 5.35)	3.67 (3.46 to 3.88)	5.31 (4.25 to 6.39)	1.20 (1.10 to 1.31)	1.13 (1.11 to 1.15)
United Kingdom	1.58 (1.51 to 1.66)	1.61 (1.60 to 1.62)	1.02 (0.95 to 1.09)	1.30 (1.29 to 1.31)	0.36 (0.14 to 0.58)	0.23 (0.22 to 0.25)
United Republic of Tanzania	3.80 (3.74 to 3.87)	4.52 (4.51 to 4.53)	0.94 (0.92 to 0.97)	2.01 (2.00 to 2.03)	0.68 (0.61 to 0.75)	0.70 (0.70 to 0.71)
United States of America	2.78 (2.71 to 2.84)	1.66 (1.63 to 1.69)	1.86 (1.79 to 1.94)	1.36 (1.34 to 1.38)	0.71 (0.65 to 0.77)	0.67 (0.66 to 0.68)
United States Virgin Islands	3.79 (3.73 to 3.85)	0.42 (0.39 to 0.45)	3.82 (3.76 to 3.88)	0.89 (0.87 to 0.91)	0.85 (0.71 to 1.00)	0.75 (0.74 to 0.76)
Uruguay	2.37 (2.26 to 2.49)	1.83 (1.82 to 1.84)	2.06 (1.94 to 2.18)	1.71 (1.71 to 1.72)	1.18 (1.06 to 1.29)	1.10 (1.07 to 1.12)
Uzbekistan	2.51 (2.12 to 2.91)	4.02 (3.99 to 4.05)	0.94 (0.50 to 1.39)	3.19 (3.14 to 3.25)	0.43 (0.25 to 0.61)	0.29 (0.28 to 0.31)
Vanuatu	3.60 (3.46 to 3.74)	3.21 (3.20 to 3.22)	1.17 (1.05 to 1.28)	1.43 (1.40 to 1.45)	0.23 (0.04 to 0.42)	0.16 (0.11 to 0.20)
Venezuela (Bolivarian Republic of)	5.03 (4.95 to 5.11)	3.44 (3.42 to 3.45)	2.99 (2.69 to 3.30)	2.87 (2.86 to 2.89)	0.96 (0.71 to 1.21)	1.06 (1.06 to 1.07)

Viet Nam	4.23 (4.09 to 4.37)	3.83 (3.79 to 3.86)	2.82 (2.69 to 2.94)	3.59 (3.56 to 3.62)	1.11 (1.04 to 1.19)	1.17 (1.15 to 1.20)
Yemen	4.91 (4.83 to 4.98)	4.83 (4.82 to 4.84)	1.86 (1.78 to 1.94)	3.24 (3.21 to 3.28)	1.28 (1.19 to 1.38)	1.38 (1.37 to 1.40)
Zambia	3.49 (3.44 to 3.54)	4.94 (4.92 to 4.95)	0.50 (0.45 to 0.54)	2.73 (2.71 to 2.74)	0.58 (0.28 to 0.88)	0.32 (0.32 to 0.33)
Zimbabwe	2.14 (2.06 to 2.22)	3.30 (3.27 to 3.32)	0.64 (0.58 to 0.70)	1.46 (1.42 to 1.49)	0.11 (0.00 to 0.22)	0.14 (0.13 to 0.15)

References

1. Jiang Y, Zhang S, Chen Y, et al. Physical activity and risk of Parkinson's disease: an updated systematic review and meta-analysis. *J Neurol* 2024;271:7434-7459.
2. Noyce AJ, Bestwick JP, Silveira-Moriyama L, et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. *Ann Neurol* 2012;72:893-901.
3. GBD 2016 Dementia Collaborators. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol* 2019;18:88-106.
4. Wang F, Wang J, Alan E, Gelfand., Li F. Disease Mapping with Generative Models. *The American Statistician* 2016;73:213-223.
5. Wafa HA, Wolfe CDA, Emmett E, et al. Burden of Stroke in Europe: Thirty-Year Projections of Incidence, Prevalence, Deaths, and Disability-Adjusted Life Years. *Stroke* 2020;51:2418-2427.
6. GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet* 2023;402:203-234.
7. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. *Stat Med* 2000;19:335-351.
8. Huang J, Chan SC, Lok V, et al. The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. *Lancet Haematol* 2022;9:e670-e677.
9. Das Gupta P. A general method of decomposing a difference between two rates into several components. *Demography* 1978;15:99-112.
10. Mansournia MA, Altman DG. Population attributable fraction. *Bmj* 2018;360:k757.
11. Eide GE, Heuch I. Attributable fractions: fundamental concepts and their visualization. *Stat Methods Med Res* 2001;10:159-193.
12. Rockhill B, Newman B, Weinberg C. Use and misuse of population attributable fractions. *Am J Public Health* 1998;88:15-19.
13. de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. *Lancet Oncol* 2012;13:607-615.
14. Hanley JA. A heuristic approach to the formulas for population attributable fraction. *J Epidemiol Community Health* 2001;55:508-514.
15. Kehoe T, Gmel G, Shield KD, Gmel G, Rehm J. Determining the best population-level alcohol consumption model and its impact on estimates of alcohol-attributable harms. *Popul Health Metr* 2012;10:6.
16. Jørgensen K, Nielsen TR, Nielsen A, Waldemar G. Potential for prevention of dementia in Denmark. *Alzheimers Dement* 2023;19:4590-4598.
17. Grandinetti A, Morens DM, Reed D, MacEachern D. Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson's disease. *Am J Epidemiol* 1994;139:1129-1138.
18. Hernán MA, Zhang SM, Rueda-deCastro AM, et al. Cigarette smoking and the incidence of Parkinson's disease in two prospective studies. *Ann Neurol* 2001;50:780-786.
19. O'Reilly EJ, McCullough ML, Chao A, et al. Smokeless tobacco use and the risk of Parkinson's disease mortality. *Mov Disord* 2005;20:1383-1384.

20. Thacker EL, O'Reilly EJ, Weisskopf MG, et al. Temporal relationship between cigarette smoking and risk of Parkinson disease. *Neurology* 2007;68:764-768.
21. Tan LC, Koh WP, Yuan JM, et al. Differential effects of black versus green tea on risk of Parkinson's disease in the Singapore Chinese Health Study. *Am J Epidemiol* 2008;167:553-560.
22. Chen H, Huang X, Guo X, et al. Smoking duration, intensity, and risk of Parkinson disease. *Neurology* 2010;74:878-884.
23. Kyrozi A, Ghika A, Stathopoulos P, et al. Dietary and lifestyle variables in relation to incidence of Parkinson's disease in Greece. *Eur J Epidemiol* 2013;28:67-77.
24. Mappin-Kasirer B, Pan H, Lewington S, et al. Tobacco smoking and the risk of Parkinson disease: A 65-year follow-up of 30,000 male British doctors. *Neurology* 2020;94:e2132-e2138.
25. Kim R, Yoo D, Jung YJ, Han K, Lee JY. Sex differences in smoking, alcohol consumption, and risk of Parkinson's disease: A nationwide cohort study. *Parkinsonism Relat Disord* 2020;71:60-65.
26. Nie J, Liu C, Yu C, et al. Independent and Joint Associations of Tea Consumption and Smoking with Parkinson's Disease Risk in Chinese Adults. *J Parkinsons Dis* 2022;12:1693-1702.
27. Sundbøll J, Szépligeti SK, Szentkúti P, et al. Risk of Parkinson Disease and Secondary Parkinsonism in Myocardial Infarction Survivors. *J Am Heart Assoc* 2022;11:e022768.
28. Song L, Zhang S, Li H, et al. Comparison of risk factors for Parkinson's disease, coronary events and ischemic stroke. *NPJ Parkinsons Dis* 2022;8:107.
29. Kizza J, Lewington S, Mappin-Kasirer B, et al. Cardiovascular risk factors and Parkinson's disease in 500,000 Chinese adults. *Ann Clin Transl Neurol* 2019;6:624-632.
30. Müller J, Myers J. Association between physical fitness, cardiovascular risk factors, and Parkinson's disease. *Eur J Prev Cardiol* 2018;25:1409-1415.
31. Yang F, Pedersen NL, Ye W, et al. Moist smokeless tobacco (Snus) use and risk of Parkinson's disease. *Int J Epidemiol* 2017;46:872-880.
32. Gallo V, Vineis P, Cancellieri M, et al. Exploring causality of the association between smoking and Parkinson's disease. *Int J Epidemiol* 2019;48:912-925.
33. Kim IY, O'Reilly É J, Hughes KC, et al. Integration of risk factors for Parkinson disease in 2 large longitudinal cohorts. *Neurology* 2018;90:e1646-e1653.
34. Liu Z, Roosaar A, Axéll T, Ye W. Tobacco Use, Oral Health, and Risk of Parkinson's Disease. *Am J Epidemiol* 2017;185:538-545.
35. Marttila RJ, Rinne UK. Smoking and Parkinson's disease. *Acta Neurol Scand* 1980;62:322-325.
36. Barbeau A, Pourcher E. New data on the genetics of Parkinson's disease. *Can J Neurol Sci* 1982;9:53-60.
37. Godwin-Austen RB, Lee PN, Marmot MG, Stern GM. Smoking and Parkinson's disease. *J Neurol Neurosurg Psychiatry* 1982;45:577-581.
38. Rajput AH, Offord KP, Beard CM, Kurland LT. A case-control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson's disease. *Neurology* 1987;37:226-232.
39. Hofman A, Collette HJ, Bartelds AI. Incidence and risk factors of Parkinson's disease in The Netherlands. *Neuroepidemiology* 1989;8:296-299.
40. Mayeux R, Tang MX, Marder K, Côté LJ, Stern Y. Smoking and Parkinson's disease. *Mov Disord* 1994;9:207-212.
41. Martyn CN, Osmond C. Parkinson's disease and the environment in early life. *J Neurol Sci* 1995;132:201-206.

42. Hellenbrand W, Seidler A, Robra BP, et al. Smoking and Parkinson's disease: a case-control study in Germany. *Int J Epidemiol* 1997;26:328-339.
43. Tzourio C, Rocca WA, Breteler MM, et al. Smoking and Parkinson's disease. An age-dependent risk effect? The EUROPARKINSON Study Group. *Neurology* 1997;49:1267-1272.
44. Chan DK, Woo J, Ho SC, et al. Genetic and environmental risk factors for Parkinson's disease in a Chinese population. *J Neurol Neurosurg Psychiatry* 1998;65:781-784.
45. Fall PA, Fredrikson M, Axelson O, Granérus AK. Nutritional and occupational factors influencing the risk of Parkinson's disease: a case-control study in southeastern Sweden. *Mov Disord* 1999;14:28-37.
46. Kuopio AM, Marttila RJ, Helenius H, Rinne UK. Environmental risk factors in Parkinson's disease. *Mov Disord* 1999;14:928-939.
47. Benedetti MD, Bower JH, Maraganore DM, et al. Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case-control study. *Neurology* 2000;55:1350-1358.
48. Paganini-Hill A. Risk factors for parkinson's disease: the leisure world cohort study. *Neuroepidemiology* 2001;20:118-124.
49. Checkoway H, Powers K, Smith-Weller T, et al. Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. *Am J Epidemiol* 2002;155:732-738.
50. Dong JQ, Zhang ZX, Zhang KL. Parkinson's disease and smoking: an integral part of PD's etiological study. *Biomed Environ Sci* 2003;16:173-179.
51. Levecque C, Elbaz A, Clavel J, et al. Association between Parkinson's disease and polymorphisms in the nNOS and iNOS genes in a community-based case-control study. *Hum Mol Genet* 2003;12:79-86.
52. Galanaud JP, Elbaz A, Clavel J, et al. Cigarette smoking and Parkinson's disease: a case-control study in a population characterized by a high prevalence of pesticide exposure. *Mov Disord* 2005;20:181-189.
53. Scott WK, Zhang F, Stajich JM, et al. Family-based case-control study of cigarette smoking and Parkinson disease. *Neurology* 2005;64:442-447.
54. Wirdefeldt K, Gatz M, Pawitan Y, Pedersen NL. Risk and protective factors for Parkinson's disease: a study in Swedish twins. *Ann Neurol* 2005;57:27-33.
55. Dhillon AS, Tarbutton GL, Levin JL, et al. Pesticide/environmental exposures and Parkinson's disease in East Texas. *J Agromedicine* 2008;13:37-48.
56. Tanaka K, Miyake Y, Fukushima W, et al. Active and passive smoking and risk of Parkinson's disease. *Acta Neurol Scand* 2010;122:377-382.
57. Nicoletti A, Pugliese P, Nicoletti G, et al. Voluptuary habits and clinical subtypes of Parkinson's disease: the FRAGAMP case-control study. *Mov Disord* 2010;25:2387-2394.
58. Sipetic SB, Vlajinac HD, Maksimovic JM, et al. Cigarette smoking, coffee intake and alcohol consumption preceding Parkinson's disease: a case-control study. *Acta Neuropsychiatr* 2012;24:109-114.
59. Belvisi D, Pellicciari R, Fabbrini A, et al. Relationship between risk and protective factors and clinical features of Parkinson's disease. *Parkinsonism Relat Disord* 2022;98:80-85.
60. Chen H, Zhang SM, Schwarzschild MA, Hernán MA, Ascherio A. Physical activity and the risk of Parkinson disease. *Neurology* 2005;64:664-669.
61. Logroscino G, Sesso HD, Paffenbarger RS, Jr., Lee IM. Physical activity and risk of Parkinson's disease: a prospective cohort study. *J Neurol Neurosurg Psychiatry* 2006;77:1318-1322.

62. Sääksjärvi K, Knekt P, Männistö S, et al. Reduced risk of Parkinson's disease associated with lower body mass index and heavy leisure-time physical activity. *Eur J Epidemiol* 2014;29:285-292.
63. Sasco AJ, Paffenbarger RS, Jr., Gendre I, Wing AL. The role of physical exercise in the occurrence of Parkinson's disease. *Arch Neurol* 1992;49:360-365.
64. Thacker EL, Chen H, Patel AV, et al. Recreational physical activity and risk of Parkinson's disease. *Mov Disord* 2008;23:69-74.
65. Xu Q, Park Y, Huang X, et al. Physical activities and future risk of Parkinson disease. *Neurology* 2010;75:341-348.
66. Yang F, Trolle Lagerros Y, Belloc R, et al. Physical activity and risk of Parkinson's disease in the Swedish National March Cohort. *Brain* 2015;138:269-275.
67. Llamas-Velasco S, Contador I, Méndez-Guerrero A, et al. Physical activity and risk of Parkinson's disease and parkinsonism in a prospective population-based study (NEDICES). *Prev Med Rep* 2021;23:101485.
68. Oveisgharan S, Yu L, Dawe RJ, Bennett DA, Buchman AS. Total Daily Physical Activity and the Risk of Parkinsonism in Community-Dwelling Older Adults. *J Gerontol A Biol Sci Med Sci* 2020;75:702-711.
69. Portugal B, Artaud F, Degaey I, et al. Association of Physical Activity and Parkinson Disease in Women: Long-term Follow-up of the E3N Cohort Study. *Neurology* 2023;101:e386-e398.
70. Shih IF, Liew Z, Krause N, Ritz B. Lifetime occupational and leisure time physical activity and risk of Parkinson's disease. *Parkinsonism Relat Disord* 2016;28:112-117.
71. Shih IF, Starhof C, Lassen CF, et al. Occupational and recreational physical activity and Parkinson's disease in Denmark. *Scand J Work Environ Health* 2017;43:210-216.
72. Frigerio R, Elbaz A, Sanft KR, et al. Education and occupations preceding Parkinson disease: a population-based case-control study. *Neurology* 2005;65:1575-1583.
73. Belvisi D, Pellicciari R, Fabbrini A, et al. Risk factors of Parkinson disease: Simultaneous assessment, interactions, and etiologic subtypes. *Neurology* 2020;95:e2500-e2508.
74. Zhu D, Liu GY, Lv Z, et al. Inverse associations of outdoor activity and vitamin D intake with the risk of Parkinson's disease. *J Zhejiang Univ Sci B* 2014;15:923-927.